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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/
10.1111/bph.13354/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated
ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information
on the best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related
targets. It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data
presented in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR
classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent,
citable, point-in-time record that will survive database updates.
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Overview: Enzymes are protein catalysts facilitating the conver-
sion of substrates into products. The Nomenclature Committee of
the International Union of Biochemistry and Molecular Biology
(NC-IUBMB) classifies enzymes into families, using a four num-
ber code, on the basis of the reactions they catalyse. There are six
main families:
EC 1.-.-.- Oxidoreductases;
EC 2.-.-.- Transferases;
EC 3.-.-.- Hydrolases;
EC 4.-.-.- Lyases;
EC 5.-.-.- Isomerases;
EC 6.-.-.- Ligases.
Although there are many more enzymes than receptors in bi-
ology, and many drugs that target prokaryotic enzymes are ef-
fective medicines, overall the number of enzyme drug targets is
relatively small [367, 401], which is not to say that they are of
modest importance.
The majority of drugs which act on enzymes act as inhibitors;
one exception is metformin, which appears to stimulate activity
of AMP-activated protein kinase, albeit through an imprecisely-
defined mechanism. Kinetic assays allow discrimination of com-
petitive, non-competitive, and un-competitive inhibitors. The
majority of inhibitors are competitive (acting at the enzyme’s
ligand recognition site), non-competitive (acting at a distinct
site; potentially interfering with co-factor or co-enzyme binding)
or of mixed type. One rare example of an uncompetitive in-
hibitor is lithium ions, which are effective inhibitors at inositol
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monophosphatase only in the presence of high substrate con-
centrations. Some inhibitors are irreversible, including a group
known as suicide substrates, which bind to the ligand recogni-
tion site and then couple covalently to the enzyme. It is beyond
the scope of the Guide to give mechanistic information about the
inhibitors described, although generally this information is avail-
able from the indicated literature.
Many enzymes require additional entities for functional activity.
Some of these are used in the catalytic steps, while others pro-
mote a particular conformational change. Co-factors are tightly
bound to the enzyme and include metal ions and heme groups.
Co-enzymes are typically small molecules which accept or donate
functional groups to assist in the enzymatic reaction. Examples
include ATP, NAD, NADP and S-adenosylmethionine, as well as a
number of vitamins, such as riboflavin (vitamin B1) and thiamine
(vitamin B2). Where co-factors/co-enzymes have been identified,
the Guide indicates their involvement.
Family structure
This is a complete listing of enzyme families included in the online IUPHAR/BPS Guide to PHARMACOLOGY database. Summary information is provided for a subset of enzyme families (those with page
numbers) in the tables below. Family members judged to be of significant pharmacological interest have been included, with further enzymes listed in the database.
6028 Protein Kinases (EC 2.7.x.x)
– AGC: Containing PKA, PKC, PKG families
– DMPK family
– GEK subfamily
– Other DMPK family kinases
6028 Rho kinase
– G protein-coupled receptor kinases
– BARK/GRK2 subfamily
– GRK1/3 subfamily
– MAST family
– NDR family
– PDK1 family
– Protein kinase A
– Akt (Protein kinase B)
6029 Protein kinase C (PKC)
6029 Alpha subfamily
6029 Delta subfamily
6030 Eta subfamily
– Iota subfamily
– Protein kinase G (PKG)
– Protein kinase N (PKN) family
– RSK family
– MSK subfamily
– p70 subfamily
– RSK subfamily
– RSKR subfamily
– RSKL family
– SGK family
– YANK family
– Atypical
– ABC1 family
– ABC1-A subfamily
– ABC1-B subfamily
– Alpha kinase family
– ChaK subfamily
– eEF2K subfamily
– Other alpha kinase family kinases
– BCR family
– Bromodomain kinase (BRDK) family
– G11 family
– Phosphatidyl inositol 3’ kinase-related kinases
(PIKK) family
– ATR subfamily
6030 FRAP subfamily
– SMG1 subfamily
– TRRAP subfamily
– Other PIKK family kinases
– RIO family
– RIO1 subfamily
– RIO2 subfamily
– RIO3 subfamily
– PDHK family
– Pyruvate dehydrogenase kinase (PDHK) family
– TAF1 family
– TIF1 family
– CAMK: Calcium/calmodulin-dependent protein
kinases
– CAMK-like (CAMKL) family
– AMPK subfamily
– BRSK subfamily
– CHK1 subfamily
– HUNK subfamily
– LKB subfamily
– MARK subfamily
– MELK subfamily
– NIM1 subfamily
– NuaK subfamily
– PASK subfamily
– QIK subfamily
– SNRK subfamily
– CAMK-unique family
– CASK family
– DCAMKL family
– Death-associated kinase (DAPK) family
– MAPK-Activated Protein Kinase (MAPKAPK)
family
– MAPKAPK subfamily
– MKN subfamily
– Myosin Light Chain Kinase (MLCK) family
– Phosphorylase kinase (PHK) family
– PIM family
– Protein kinase D (PKD) family
– PSK family
– RAD53 family
– Trbl family
– Trio family
– CK1: Casein kinase 1
– Casein kinase 1 (CK1) family
– Tau tubulin kinase (TTBK) family
– Vaccina related kinase (VRK) family
– CMGC: Containing CDK, MAPK, GSK3, CLK families
– CLK family
– Cyclin-dependent kinase (CDK) family
– CCRK subfamily
– CDK1 subfamily
6031 CDK4 subfamily
– CDK5 subfamily
– CDK7 subfamily
– CDK8 subfamily
– CDK9 subfamily
– CDK10 subfamily
– CRK7 subfamily
– PITSLRE subfamily
– TAIRE subfamily
– Cyclin-dependent kinase-like (CDKL) family
– Dual-specificity tyrosine-(Y)-phosphorylation
regulated kinase (DYRK) family
– Dyrk1 subfamily
– Dyrk2 subfamily
– HIPK subfamily
– PRP4 subfamily
– Glycogen synthase kinase (GSK) family
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6031 GSK subfamily
– Mitogen-activated protein kinases (MAP kinases)
– ERK subfamily
– Erk7 subfamily
– JNK subfamily
– p38 subfamily
– nmo subfamily
– RCK family
– SRPK family
– Other protein kinases
– CAMKK family
– Meta subfamily
– Aurora kinase (Aur) family
– Bub family
– Bud32 family
– Casein kinase 2 (CK2) family
– CDC7 family
– Haspin family
– IKK family
– IRE family
– MOS family
– NAK family
– NIMA (never in mitosis gene a)- related kinase
(NEK) family
– NKF1 family
– NKF2 family
– NKF4 family
– NKF5 family
– NRBP family– Numb-associated kinase (NAK) family
– Other-unique family
6032 Polo-like kinase (PLK) family
– PEK family
– GCN2 subfamily
– PEK subfamily
– Other PEK family kinases
– SgK493 family
– Slob family
– TBCK family
– TOPK family
– Tousled-like kinase (TLK) family
– TTK family
– Unc-51-like kinase (ULK) family
– VPS15 family
– WEE family
– Wnk family
– Miscellaneous protein kinases
– actin-binding proteins ADF family
– Twinfilin subfamily
– SCY1 family
– Hexokinases
– STE: Homologs of yeast Sterile 7, Sterile 11, Sterile
20 kinases
6032 STE7 family
– STE11 family
– STE20 family
– FRAY subfamily
– MSN subfamily
– NinaC subfamily
– PAKA subfamily
– PAKB subfamily
– STLK subfamily
– TAO subfamily
– STE20 family
– STE-unique family
– TK: Tyrosine kinase
6033 Abl family
6033 Ack family
– Csk family
– Fak family
– Fer family
6034 Janus kinase (JakA) family
6034 Src family
– Syk family
6035 Tec family
– TKL: Tyrosine kinase-like
– Interleukin-1 receptor-associated kinase
(IRAK) family
– Leucine-rich repeat kinase (LRRK) family
– LIM domain kinase (LISK) family
– LIMK subfamily
– TESK subfamily
– Mixed Lineage Kinase (MLK) family
– HH498 subfamily
– ILK subfamily
– LZK subfamily
– MLK subfamily
– TAK1 subfamily
6035 RAF family
– Receptor interacting protein kinase (RIPK)
family
– TKL-unique family
6036 Peptidases and proteinases
– AA: Aspartic (A) Peptidases
6036 A1: Pepsin
– AD: Aspartic (A) Peptidases
6037 A22: Presenilin
– CA: Cysteine (C) Peptidases
– C1: Papain
– C2: Calpain
– C12: Ubiquitin C-terminal hydrolase
– C19: Ubiquitin-specific protease
– C54: Aut2 peptidase
– CD: Cysteine (C) Peptidases
– C13: Legumain
6037 C14: Caspase
– CE: Cysteine (C) Peptidases
– C48: Ulp1 endopeptidase
– M-: Metallo (M) Peptidases
– M79: Prenyl protease 2
– MA: Metallo (M) Peptidases
6037 M1: Aminopeptidase N
6038 M2: Angiotensin-converting (ACE and ACE2)
6038 M10: Matrix metallopeptidase
6039 M12: Astacin/Adamalysin
– M13: Neprilysin
– M49: Dipeptidyl-peptidase III
– MC: Metallo (M) Peptidases
– M14: Carboxypeptidase A
– ME: Metallo (M) Peptidases
– M16: Pitrilysin
– MF: Metallo (M) Peptidases
– M17: Leucyl aminopeptidase
– MG: Metallo (M) Peptidases
– M24: Methionyl aminopeptidase
– MH: Metallo (M) Peptidases
– M18: Aminopeptidase I
– M20: Carnosine dipeptidase
6039 M28: Aminopeptidase Y
– MJ: Metallo (M) Peptidases
6040 M19: Membrane dipeptidase
– MP: Metallo (M) Peptidases
– M67: PSMD14 peptidase
– PA: Serine (S) Peptidases
6040 S1: Chymotrypsin
– PB: Threonine (T) Peptidases
6041 T1: Proteasome
– T2: Glycosylasparaginase precursor
– PC: Cysteine (C) Peptidases
– C26: Gamma-glutamyl hydrolase
– SB: Serine (S) Peptidases
6042 S8: Subtilisin
– SC: Serine (S) Peptidases
6042 S9: Prolyl oligopeptidase
– S10: Carboxypeptidase Y
– S28: Lysosomal Pro-Xaa carboxypeptidase
– S33: prolyl aminopeptidase
6042 Acetylcholine turnover
6044 Adenosine turnover
6045 Amino acid hydroxylases
6046 L-Arginine turnover
6047 Arginase
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6047 Arginine:glycine amidinotransferase
6047 Dimethylarginine dimethylaminohydrolases
6048 Nitric oxide synthases
6048 Carboxylases and decarboxylases
6049 Carboxylases
6050 Decarboxylases
6052 Catecholamine turnover
6055 Ceramide turnover
6055 Serine palmitoyltransferase
– 3-ketodihydrosphingosine reductase
6056 Ceramide synthase
6057 Sphingolipid 14-desaturase
6058 Sphingomyelin synthase
6058 Sphingomyelin phosphodiesterase
6059 Neutral sphingomyelinase coupling factors
6059 Ceramide glucosyltransferase
6060 Acid ceramidase
6060 Neutral ceramidases
6061 Alkaline ceramidases
6061 Ceramide kinase
6062 Chromatin modifying enzymes
– Enzymatic bromodomain-containing proteins
– Bromodomain kinase (BRDK) family
– TAF1 family
– TIF1 family
– 1.14.11.- Histone demethylases
– 2.1.1.43 Histone methyltransferases (HMTs)
– 2.3.1.48 Histone acetyltransferases (HATs)
– 3.6.1.3 ATPases
6062 2.1.1.- Protein arginine N-methyltransferases
6062 3.5.1.- Histone deacetylases (HDACs)
6063 Cyclic nucleotide turnover
6063 Adenylyl cyclases
6064 Soluble guanylyl cyclase
6065 Exchange protein activated by cyclic AMP (Epac)
6066 Phosphodiesterases, 3’,5’-cyclic nucleotide
6069 Cytochrome P450
6069 CYP1 family
6070 CYP2 family
6070 CYP3 family
6071 CYP4 family
6072 CYP5, CYP7 and CYP8 families
6072 CYP11, CYP17, CYP19, CYP20 and CYP21 families
6073 CYP24, CYP26 and CYP27 families
6074 CYP39, CYP46 and CYP51 families
6076 Eicosanoid turnover
6075 Endocannabinoid turnover
6077 Cyclooxygenase
6077 Prostaglandin synthases
6079 Lipoxygenases
6080 Leukotriene and lipoxin metabolism
6081 GABA turnover
6082 Glycerophospholipid turnover
– Lipid modifying kinases
6083 1-phosphatidylinositol 4-kinase family
6083 Phosphatidylinositol-4-phosphate 3-kinase family
6084 Phosphatidylinositol 3-kinase family
6084 Phosphatidylinositol-4,5-bisphosphate 3-kinase
family
6085 1-phosphatidylinositol-3-phosphate 5-kinase
family
6085 Type I PIP kinases (1-phosphatidylinositol-4-
phosphate 5-kinase family)
6086 Type II PIP kinases (1-phosphatidylinositol-5-
phosphate 4-kinase family)
6100 Sphingosine kinase
6087 Phosphoinositide-specific phospholipase C
6088 Phospholipase A2
6089 Phosphatidylcholine-specific phospholipase D
6090 Lipid phosphate phosphatases
6082 Phosphatidylinositol kinases
6091 Haem oxygenase
6092 Hydrogen sulphide synthesis
6093 Hydrolases
6093 Inositol phosphate turnover
6094 Inositol 1,4,5-trisphosphate 3-kinases
6094 Inositol polyphosphate phosphatases
6094 Inositol monophosphatase
6095 Lanosterol biosynthesis pathway
6097 Nucleoside synthesis and metabolism
6099 Sphingosine 1-phosphate turnover
6100 Sphingosine kinase
6100 Sphingosine 1-phosphate phosphatase
6101 Sphingosine 1-phosphate lyase
6101 Thyroid hormone turnover
– 1.4.3.13 Lysyl oxidases
– 1.13.11.- Dioxygenases
6103 1.14.11.29 2-oxoglutarate oxygenases
transferases
– 2.3.-.- Acyltransferases
6103 2.4.2.30 poly(ADP-ribose)polymerases
6104 2.5.1.58 Protein farnesyltransferase
– 3.1.-.- Ester bond enzymes
– 3.1.1.- Carboxylic Ester Hydrolases
– 3.2.1.- Glycosidases
– 3.4.21.46 Complement factor D
6062 3.5.1.- Histone deacetylases (HDACs)
6104 3.5.3.15 Peptidyl arginine deiminases (PADI)
– 3.6.5.2 Small monomeric GTPases
6104 RAS subfamily
6105 4.2.1.1 Carbonate dehydratases
– 5.-.-.- Isomerases
– 5.2.-.- Cis-trans-isomerases
6105 5.99.1.2 DNA Topoisomerases
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Protein Kinases (EC 2.7.x.x)
Enzymes! Kinases (EC 2.7.x.x)
Overview: Protein kinases (E.C. 2.7.11.-) use the co-substrate ATP
to phosphorylate serine and/or threonine residues on target pro-
teins. Analysis of the human genome suggests the presence of 518
protein kinases in man, with over 100 protein kinase-like pseudo-
genes [313]. It is beyond the scope of the Concise Guide to list
all these protein kinase activities; the full listing may be seen at
www.GuidetoPHARMACOLOGY.org.
Most inhibitors of these enzymes have been assessed in cell-free
investigations and so may appear to ‘lose’ potency and selectiv-
ity in intact cell assays. In particular, ambient ATP concentrations
may be influential in responses to inhibitors, since the majority
are directed at the ATP binding site [103] .
Further Reading
Eglen R et al. (2011) Drug discovery and the human kinome: recent trends. Pharmacol. Ther. 130:
144-56 [PMID:21256157]
Graves LM et al. (2013) The dynamic nature of the kinome. Biochem. J. 450: 1-8 [PMID:23343193]
Liu Q et al. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol.
20: 146-59 [PMID:23438744]
Martin KJ et al. (2012) Selective kinase inhibitors as tools for neuroscience research. Neuropharma-
cology 63: 1227-37 [PMID:22846224]
Tarrant MK et al. (2009) The chemical biology of protein phosphorylation. Annu. Rev. Biochem. 78:
797-825 [PMID:19489734]
Wu-Zhang AX et al. (2013) Protein kinase C pharmacology: refining the toolbox. Biochem. J. 452:
195-209 [PMID:23662807]
Rho kinase
Enzymes! Kinases (EC 2.7.x.x)! AGC: Containing PKA, PKG, PKC families! DMPK family! Rho kinase
Overview: Rho kinase (also known as P160ROCK, Rho-activated kinase) is activated by members of the Rho small G protein family, which are activated by GTP exchange factors, such as ARHGEF1
(Q92888, p115-RhoGEF), which in turn may be activated by Gα12/13 subunits [269].
Nomenclature Rho-associated, coiled-coil containing protein kinase 1 Rho-associated, coiled-coil containing protein kinase 2
Systematic nomenclature ROCK1 ROCK2
Common abreviation Rho kinase 1 Rho kinase 2
HGNC, UniProt ROCK1, Q13464 ROCK2, O75116
EC number 2.7.11.1 2.7.11.1
Inhibitors RKI-1447 (pIC50 >9) [387], Y27632 (pIC50 7.3) [529], fasudil (pKi
7) [403], Y27632 (pKi 6.8) [496], fasudil (pIC50 5.5) [403]
RKI-1447 (pIC50 >9) [387], compound 11d [DOI: 10.1039/c0md00194e] (pIC50 >9)
[77], GSK269962A (pIC50 8.4) [118], compound 32 [PMID: 20471253] (pIC50 8.4)
[45], compound 22 [PMID: 20462760] (pIC50 7.7) [529], Y27632 (pIC50 7.2) [529],
Y27632 (pKi 6.8) [496], fasudil (pIC50 5.9) [403]
Selective inhibitors GSK269962A (pIC50 8.8) [118] –
Searchable database: http://www.guidetopharmacology.org/index.jsp Rho kinase 6028
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Protein kinase C (PKC)
Enzymes! Kinases (EC 2.7.x.x)! AGC: Containing PKA, PKG, PKC families! Protein kinase C (PKC)
Overview: Protein kinase C is the target for the tumour-
promoting phorbol esters, such as tetradecanoyl-β-phorbol acetate
(TPA, also known as phorbol 12-myristate 13-acetate).
Classical protein kinase C isoforms: PKCα, PKCβ, PKCγ. Mem-
bers of the classical protein kinase C family are activated by
Ca2+ and diacylglycerol, and may be inhibited by GF109203X,
calphostin C, GÖ 6983, chelerythrine and Ro31-8220.
Novel protein kinase C isoforms: PKCÆ, PKC, PKC, PKC and
PKC. Members of the classical protein kinase C family are ac-
tivated by diacylglycerol and may be inhibited by calphostin C,
GÖ 6983 and chelerythrine.
Atypical protein kinase C isoforms:PKC, PKC .
Alpha subfamily
Enzymes! Kinases (EC 2.7.x.x)! AGC: Containing PKA, PKG, PKC families! Protein kinase C (PKC)! Alpha subfamily
Nomenclature protein kinase C, beta protein kinase C, gamma
Common abreviation PKCβ PKCγ
HGNC, UniProt PRKCB, P05771 PRKCG, P05129
EC number 2.7.11.13 2.7.11.13
Inhibitors sotrastaurin (pIC50 8.7) [506], GÖ 6983 (pIC50 8.1) [183], GF109203X (pIC50 7.8) [490] –
Bovine, 7-hydroxystaurosporine (pIC50 7.5) [431]
GÖ 6983 (pIC50 8.2) [183], 7-hydroxystaurosporine (pIC50
7.5) [431]
Selective inhibitors ruboxistaurin (pIC50 8.2) [238], enzastaurin (pIC50 7.5) [132], CGP53353 (pIC50 6.4) [70] –
Delta subfamily
Enzymes! Kinases (EC 2.7.x.x)! AGC: Containing PKA, PKG, PKC families! Protein kinase C (PKC)! Delta subfamily
Nomenclature protein kinase C, alpha protein kinase C, delta
Common abreviation PKCα PKCÆ
HGNC, UniProt PRKCA, P17252 PRKCD, Q05655
EC number 2.7.11.13 2.7.11.13
Activators – ingenol mebutate (pKi 9.4) [252]
Searchable database: http://www.guidetopharmacology.org/index.jsp Delta subfamily 6029
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(continued)
Nomenclature protein kinase C, alpha protein kinase C, delta
Inhibitors sotrastaurin (pIC50 8.7) [506], GÖ 6983 (pIC50 8.1) [183], 7-hydroxystaurosporine
(pIC50 7.5) [431]
sotrastaurin (pIC50 8.9) [506], GÖ 6983 (pIC50 8) [183]
Eta subfamily
Enzymes! Kinases (EC 2.7.x.x)! AGC: Containing PKA, PKG, PKC families! Protein kinase C (PKC)! Eta subfamily
Nomenclature protein kinase C, epsilon
Common abreviation PKC
HGNC, UniProt PRKCE, Q02156
EC number 2.7.11.13
Inhibitors sotrastaurin (pIC50 8.2) [506]
FRAP subfamily
Enzymes! Kinases (EC 2.7.x.x)! Atypical! Phosphatidyl inositol 3’ kinase-related kinases (PIKK) family! FRAP subfamily
Nomenclature mechanistic target of rapamycin (serine/threonine kinase)
Common abreviation mTOR
HGNC, UniProt MTOR, P42345
EC number 2.7.11.1
Inhibitors ridaforolimus (pIC50 9.7) [408], torin 1 (pIC50 9.5) [291], INK-128 (pIC50 9) [219], INK-128 (pKi 8.9) [219], gedatolisib (pIC50 8.8) [500], dactolisib (pIC50
8.2) [310], PP-242 (pIC50 8.1) [14], PP121 (pIC50 8) [14], XL388 (pIC50 8) [472], PF-04691502 (pKi 7.8) [290], apitolisib (pKi 7.8) [467]
Selective inhibitors everolimus (pIC50 8.7) [427], temsirolimus (pIC50 5.8) [266]
Searchable database: http://www.guidetopharmacology.org/index.jsp FRAP subfamily 6030
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CDK4 subfamily
Enzymes! Kinases (EC 2.7.x.x)! CMGC: Containing CDK, MAPK, GSK3, CLK families! Cyclin-dependent kinase (CDK) family! CDK4 subfamily
Nomenclature cyclin-dependent kinase 4 cyclin-dependent kinase 6
Common abreviation CDK4 CDK6
HGNC, UniProt CDK4, P11802 CDK6, Q00534
EC number 2.7.11.22 2.7.11.22
Inhibitors R547 (pKi 9) [107], palbociclib (pIC50 8) [151], Ro-0505124 (pIC50 7.7) [115], riviciclib (pIC50 7.2) [246],
alvocidib (pKi 7.2) [64]
palbociclib (pIC50 7.8) [151]
GSK subfamily
Enzymes! Kinases (EC 2.7.x.x)! CMGC: Containing CDK, MAPK, GSK3, CLK families! Glycogen synthase kinase (GSK) family! GSK subfamily
Nomenclature glycogen synthase kinase 3 beta
Common abreviation GSK3B
HGNC, UniProt GSK3B, P49841
EC number 2.7.11.26
Inhibitors CHIR-98014 (pIC50 9.2) [407], LY2090314 (pIC50 9) [125], CHIR-99021 (pIC50 8.2) [407], SB 216763 (pIC50 8.1) [88], 1-azakenpaullone (pIC50 7.7)
[272], SB-415286 (pIC50 7.4) [88], IM-12 (pIC50 7.3) [424]
Selective inhibitors AZD2858 (pKi 8.3) [29]
Comments Due to its Tau phosphorylating activity, small molecule inhibitors of GSK-3β are being investigated as potential treatments for Alzheimer’s disease (AD) [29].
GSK-3β also plays a role in canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is
hypothesised that small molecule inhibitors of GSK-3β may provide effective therapeutics for the treatment of diseases characterised by low bone mass [317].
Searchable database: http://www.guidetopharmacology.org/index.jsp GSK subfamily 6031
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Polo-like kinase (PLK) family
Enzymes! Kinases (EC 2.7.x.x)! Other protein kinases! Polo-like kinase (PLK) family
Nomenclature polo-like kinase 4
Common abreviation PLK4
HGNC, UniProt PLK4, O00444
EC number 2.7.11.21
Inhibitors CFI-400945 (pIC50 8.6) [320]
STE7 family
Enzymes! Kinases (EC 2.7.x.x)! STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases! STE7 family
Nomenclature mitogen-activated protein kinase kinase 1 mitogen-activated protein kinase kinase 2
Common abreviation MEK1 MEK2
HGNC, UniProt MAP2K1, Q02750 MAP2K2, P36507
EC number 2.7.12.2 2.7.12.2
Inhibitors trametinib (pIC50 9–9.1) [173, 536], PD 0325901 (pIC50 8.1) [195],
binimetinib (pIC50 7.9) [382], refametinib (pIC50 7.7) [229], CI-1040 (pKd 6.9)
[105]
trametinib (pIC50 8.7) [536], binimetinib (pIC50 7.9) [382], refametinib (pIC50
7.3) [229]
Searchable database: http://www.guidetopharmacology.org/index.jsp STE7 family 6032
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Abl family
Enzymes! Kinases (EC 2.7.x.x)! TK: Tyrosine kinase! Abl family
Nomenclature ABL proto-oncogene 1, non-receptor tyrosine kinase
Common abreviation Abl
HGNC, UniProt ABL1, P00519
EC number 2.7.10.2
Inhibitors compound 8h (pIC50 9.7) [487], dasatinib (pIC50 9.6) [258], compound 24 (pIC50 9.3) [110], PD-173955 (pKd 9.2) [105], bosutinib (pIC50 9) [176],
PD-173955 (pIC50 8.3) [346], bafetinib (pIC50 7.6–8.2) [216, 257], ponatinib (pIC50 8.1) [220], nilotinib (pIC50 7.8) [356], PP121 (pIC50 7.7) [14],
imatinib (pIC50 6.7) [216], GNF-5 (pIC50 6.7) [549]
Ack family
Enzymes! Kinases (EC 2.7.x.x)! TK: Tyrosine kinase! Ack family
Nomenclature tyrosine kinase, non-receptor, 2
Common abreviation Ack
HGNC, UniProt TNK2, Q07912
EC number 2.7.10.2
Inhibitors compound 30 (pIC50 9) [114]
Searchable database: http://www.guidetopharmacology.org/index.jsp Ack family 6033
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Janus kinase (JakA) family
Enzymes! Kinases (EC 2.7.x.x)! TK: Tyrosine kinase! Janus kinase (JakA) family
Nomenclature Janus kinase 1 Janus kinase 2 Janus kinase 3 tyrosine kinase 2
Common
abreviation
JAK1 JAK2 JAK3 Tyk2
HGNC, UniProt JAK1, P23458 JAK2, O60674 JAK3, P52333 TYK2, P29597
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors ruxolitinib
(pIC50 8.5–10.1)
[191, 395],
filgotinib (pIC50
8) [497]
NS-018 (pIC50 9.1) [350], BMS-911543 (pIC50 9) [393], AT-9283 (pIC50 8.9) [218],
XL019 (pIC50 8.7) [143], fedratinib (pIC50 8.5) [311, 521], gandotinib (pIC50 8.4)
[308]
AT-9283 (pIC50 9)
[218]
–
Selective
inhibitors
– compound 1d (pIC50 >9) [509] – –
Comments – The JAK2V617F mutation, which causes constitutive activation, plays an oncogenic
role in the pathogenesis of the myeloproliferative disorders, polycythemia vera,
essential thrombocythemia, and idiopathic myelofibrosis [58, 109]. Small molecule
compounds which inhibit aberrant JAK2 activity are being developed as novel
anti-cancer pharmaceuticals.
– –
Src family
Enzymes! Kinases (EC 2.7.x.x)! TK: Tyrosine kinase! Src family
Nomenclature BLK proto-oncogene, Src fyn-related Src family FYN proto-oncogene, Src LYN proto-oncogene, Src SRC proto-oncogene,
Src family tyrosine kinase tyrosine kinase family tyrosine kinase family tyrosine kinase non-receptor tyrosine kinase
Common
abreviation
Blk FRK Fyn Lyn Src
HGNC, UniProt BLK, P51451 FRK, P42685 FYN, P06241 LYN, P07948 SRC, P12931
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Searchable database: http://www.guidetopharmacology.org/index.jsp Src family 6034
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(continued)
Nomenclature BLK proto-oncogene, Src fyn-related Src family FYN proto-oncogene, Src LYN proto-oncogene, Src SRC proto-oncogene,
Src family tyrosine kinase tyrosine kinase family tyrosine kinase family tyrosine kinase non-receptor tyrosine kinase
Inhibitors – – – bafetinib (pIC50 8) [216] WH-4-023 (pIC50 8.2) [318],
PD166285 (pKi 8.1) [371], PP121
(pIC50 7.8) [14], ENMD-2076
(pIC50 7.7) [389]
Tec family
Enzymes! Kinases (EC 2.7.x.x)! TK: Tyrosine kinase! Tec family
Nomenclature BMX non-receptor tyrosine kinase Bruton agammaglobulinemia tyrosine kinase TXK tyrosine kinase
Common abreviation Etk Btk TXK
HGNC, UniProt BMX, P51813 BTK, Q06187 TXK, P42681
EC number 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors – ibrutinib (pIC50 9.3) [370], compound 31 [PMID: 24915291] (pIC50 8.4)
[285], compound 38 [PMID: 24915291] (pIC50 >8.4) [285]
–
Selective inhibitors – CGI1746 (pIC50 8.7) [112] –
RAF family
Enzymes! Kinases (EC 2.7.x.x)! TKL: Tyrosine kinase-like! RAF family
Nomenclature B-Raf proto-oncogene, serine/threonine kinase Raf-1 proto-oncogene, serine/threonine kinase
Common abreviation B-Raf c-Raf
HGNC, UniProt BRAF, P15056 RAF1, P04049
EC number 2.7.11.1 2.7.11.1
Searchable database: http://www.guidetopharmacology.org/index.jsp RAF family 6035
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(continued)
Nomenclature B-Raf proto-oncogene, serine/threonine kinase Raf-1 proto-oncogene, serine/threonine kinase
Inhibitors GDC-0879 (pIC50 9.7–9.9) [105, 193], dabrafenib (pIC50 8.5) [277], regorafenib
(pIC50 7.6) [545], vemurafenib (pIC50 7) [510], PLX-4720 (pKd 6.5) [105],
compound 2 [PMID: 26061392] (pKd 6.3) [215], CHIR-265 (pKd 5.9) [105]
–
Selective inhibitors – GW5074 (pIC50 8.1) [80]
Peptidases and proteinases
Enzymes! Peptidases and proteinases
Overview: Peptidases and proteinases hydrolyse peptide bonds,
and can be simply divided on the basis of whether terminal
peptide bonds are cleaved (exopeptidases and exoproteinases) at
the amino terminus (aminopeptidases) or carboxy terminus (car-
boxypeptidases). Non-terminal peptide bonds are cleaved by en-
dopeptidases and endoproteinases, which are divided into serine
endopeptidases (EC3.4.21.-), cysteine endopeptidases (EC3.4.22.-),
aspartate endopeptidases (EC 3.4.23.-), metalloendopeptidases
(EC 3.4.24.-) and threonine endopeptidases (EC 3.4.25.-). It is
beyond the scope of the Guide to list all peptidase and proteinase
activities; this summary focuses on selected enzymes of significant
pharmacological interest.
A1: Pepsin
Enzymes! Peptidases and proteinases! AA: Aspartic (A) Peptidases! A1: Pepsin
Nomenclature renin
HGNC, UniProt REN, P00797
EC number 3.4.23.15
Inhibitors aliskiren (pIC50 9.2) [532]
Searchable database: http://www.guidetopharmacology.org/index.jsp A1: Pepsin 6036
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A22: Presenilin
Enzymes! Peptidases and proteinases! AD: Aspartic (A) Peptidases! A22: Presenilin
Overview: Presenilin (PS)-1 or -2 act as the catalytic compo-
nent/essential co-factor of the γ-secretase complex responsible for
the final carboxy-terminal cleavage of amyloid precursor protein
(APP) [249] in the generation of amyloid beta (Aβ) [6, 471]. Given
that the accumulation and aggregation of Aβ in the brain is piv-
otal in the development of Alzheimer’s disease (AD), inhibition
of PS activity is one mechanism being investigated as a thera-
peutic option for AD [177]. Several small molecule inhibitors
of PS-1 have been investigated, with some reaching early clin-
ical trials, but none have been formally approved. Dewji et al
(2015) have reported that small peptide fragments of human PS-1
can significantly inhibit Aβ production (total Aβ, Aβ40 and Aβ42)
both in vitro and when infused in to the brains of APP transgenic
mice [111]. The most active small peptides in this report were
P4 [PMID: 25923432] and P8 [PMID: 25923432], from the amino-
terminal domain of PS-1.
C14: Caspase
Enzymes! Peptidases and proteinases! CD: Cysteine (C) Peptidases! C14: Caspase
Overview: Caspases, (E.C. 3.4.22.-) which derive their name
from Cysteine ASPartate-specific proteASES, include at least two
families; initiator caspases (caspases 2, 8, 9 and 10), which are able
to hydrolyse and activate a second family of effector caspases (cas-
pases 3, 6 and 7), which themselves are able to hydrolyse further
cellular proteins to bring about programmed cell death. Caspases
are heterotetrameric, being made up of two pairs of subunits, gen-
erated by a single gene product, which is proteolysed to form the
mature protein. Members of the mammalian inhibitors of apop-
tosis proteins (IAP) are able to bind the procaspases, thereby pre-
venting maturation to active proteinases.
Comments: CARD16 (Caspase recruitment domain-containing protein 16, caspase-1 inhibitor COP, CARD only domain-containing protein 1, pseudo interleukin-1β converting enzyme, pseudo-ICE,
ENSG00000204397) shares sequence similarity with some of the caspases.
M1: Aminopeptidase N
Enzymes! Peptidases and proteinases!MA: Metallo (M) Peptidases!M1: Aminopeptidase N
Overview: Aminopeptidases catalyze the cleavage of amino acids from the amino (N) terminus of protein or peptide substrates, and are involved in many essential cellular functions. Members of this
enzyme family may be monomeric or multi-subunit complexes, and many are zinc metalloenzymes [480].
Searchable database: http://www.guidetopharmacology.org/index.jsp M1: Aminopeptidase N 6037
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M2: Angiotensin-converting (ACE and ACE2)
Enzymes! Peptidases and proteinases!MA: Metallo (M) Peptidases!M2: Angiotensin-converting (ACE and ACE2)
Nomenclature Angiotensin-converting enzyme
Common abreviation ACE
HGNC, UniProt ACE, P12821
EC number 3.4.15.1
Endogenous substrates angiotensin I (AGT, P01019) > angiotensin II (AGT, P01019)
Inhibitors zofenoprilat (pKi 9.4) [270] – Rabbit, captopril (pKi 8.4) [331], zofenopril
Selective inhibitors perindoprilat (pIC50 9) [67], cilazaprilat (pIC50 8.7) [514] – Rabbit, imidaprilat (pIC50 8.7) [409], lisinopril-tryptophan (C-domain assay) (pIC50 8.2) [515],
RXP-407 (N-domain selective inhibition) (pIC50 8.1) [434], fosinoprilat (pIC50 8) [106] – Rabbit, enalaprilat (pIC50 7.5) [79], benazeprilat (pIC50 6.6) [282]
Comments Reports of ACE GPI hydrolase activity [265] have been refuted [283]
M10: Matrix metallopeptidase
Enzymes! Peptidases and proteinases!MA: Metallo (M) Peptidases!M10: Matrix metallopeptidase
Overview: Matrix metalloproteinases (MMP) are calcium- and zinc-dependent proteinases regulating the extracellular matrix and are often divided (e.g. [501]) on functional and structural bases into
gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type-MMP (MT-MMP).
Nomenclature MMP2 MMP8
HGNC, UniProt MMP2, P08253 MMP8, P22894
EC number 3.4.24.24 3.4.24.34
Selective inhibitors ARP100 [493] –
Comments: A number of small molecule ‘broad spectrum’ inhibitors of MMP have been described, including marimastat and batimastat.
Tissue inhibitors of metalloproteinase (TIMP) proteins are endogenous inhibitors acting to chelate MMP proteins: TIMP1 (TIMP1, P01033), TIMP2 (TIMP2, P16035), TIMP3 (TIMP3, P35625),
TIMP4 (TIMP4, Q99727)
Searchable database: http://www.guidetopharmacology.org/index.jsp M10: Matrix metallopeptidase 6038
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M12: Astacin/Adamalysin
Enzymes! Peptidases and proteinases!MA: Metallo (M) Peptidases!M12: Astacin/Adamalysin
Overview: ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited
products.
ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited products.
Comments: Additional ADAM familymembers include AC123767.2 (cDNA FLJ58962, moderately similar to mouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21-like protein, ENSG00000235812),
AC136428.3-2 (ENSG00000185520) and ADAMDEC1 (decysin 1, ENSG00000134028).
Other ADAMTS family members include AC104758.12-5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3-1 (ENSG00000225577), and AC126339.6-1 (ENSG00000225734).
M28: Aminopeptidase Y
Enzymes! Peptidases and proteinases!MH: Metallo (M) Peptidases!M28: Aminopeptidase Y
Nomenclature Folate hydrolase (prostate-specific membrane antigen) 1
HGNC, UniProt FOLH1, Q04609
EC number 3.4.17.21
Antibodies capromab (Binding)
Comment: folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate. In the gut, the enzyme assists in
the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up-regulated in cancerous tissue. A tagged version of
the antibody capromab has been used for imaging purposes.
Searchable database: http://www.guidetopharmacology.org/index.jsp M28: Aminopeptidase Y 6039
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M19: Membrane dipeptidase
Enzymes! Peptidases and proteinases!MJ: Metallo (M) Peptidases!M19: Membrane dipeptidase
Nomenclature Dipeptidase 1
HGNC, UniProt DPEP1, P16444
EC number 3.4.13.19: LTD4 + H2O = LTE4 + glycine
Inhibitors cilastatin (pKi 6) [179] – Unknown
S1: Chymotrypsin
Enzymes! Peptidases and proteinases! PA: Serine (S) Peptidases! S1: Chymotrypsin
Nomenclature complement component 1, r subcomponent coagulation factor II (thrombin) coagulation factor X elastase, neutrophil expressed
HGNC, UniProt C1R, P00736 F2, P00734 F10, P00742 ELANE, P08246
EC number 3.4.21.41 3.4.21.5 3.4.21.6 3.4.21.37
Inhibitors nafamostat (pIC50 4.9) [203] lepirudin (pKi 13) [511],
desirudin (pKi 12.7) [242],
AZ12971554 (pKi 9.5) [16],
melagatran (pKi 8.7) [186],
bivalirudin (pKi 8.6) [527],
dabigatran (pKi 8.3) [198],
argatroban (pKi 7.7) [225]
rivaroxaban (pKi 9.4)
[380], edoxaban (pKi
9.2) [385], apixaban (pKi
9.1) [528]
alvelestat (pKi 8) [463], sivelestat
(pIC50 7.4) [96]
Selective
inhibitors
– AR-H067637 (pIC50 8.4) [108] – –
Searchable database: http://www.guidetopharmacology.org/index.jsp S1: Chymotrypsin 6040
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Nomenclature plasminogen plasminogen activator, tissue protease, serine, 1 (trypsin 1) tryptase alpha/beta 1
HGNC, UniProt PLG, P00747 PLAT, P00750 PRSS1, P07477 TPSAB1, Q15661
EC number 3.4.21.7 3.4.21.68 3.4.21.4 3.4.21.59
Inhibitors aprotinin {Bovine} (Binding) (pIC50 6.8) [454],
tranexamic acid (Binding) (pIC50 3.6) [454],
6-aminocaproic acid (Binding)
6-aminocaproic acid nafamostat (pIC50 7.8) [203] nafamostat (pIC50 10) [342]
Selective
inhibitors
– – – gabexate (pIC50 8.5) [127]
T1: Proteasome
Enzymes! Peptidases and proteinases! PB: Threonine (T) Peptidases! T1: Proteasome
Overview: The T1 macropain beta subunits form the catalytic proteinase core of the 20S proteasome complex [86]. This catalytic core enables the degradation of peptides with Arg, Phe, Tyr, Leu, and
Glu adjacent to the cleavage site. The β5 subunit is the principal target of the approved drug proteasome inhibitor bortezomib.
Nomenclature proteasome (prosome, macropain) subunit, beta type, 5
HGNC, UniProt PSMB5, P28074
EC number 3.4.25.1
Inhibitors bortezomib (pIC50 7.7) [347]
Selective inhibitors ixazomib (pKi 9) [273]
Searchable database: http://www.guidetopharmacology.org/index.jsp T1: Proteasome 6041
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13354/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. British Journal of Pharmacology (2015) 172, 6024–6109
S8: Subtilisin
Enzymes! Peptidases and proteinases! SB: Serine (S) Peptidases! S8: Subtilisin
Overview: One member of this family has garnered intense in-
terest as a clinical drug target. As liver PCSK9 acts to maintain
cholesterol homeostasis, it has become a target of intense in-
terest for clinical drug development. Inhibition of PCSK9 can
lower low-density cholesterol (LDL-C) by clearing LDLR-bound
LDL particles, thereby lowering circulating cholesterol levels. It
is hypothesised that this action may improve outcomes in pa-
tients with atherosclerotic cardiovascular disease [297, 416, 462].
Therapeutics which inhibit PCSK9 are viewed as potentially lu-
crative replacements for statins, upon statin patent expiry. Sev-
eral monoclonal antibodies including alirocumab, evolocumab,
bococizumab, RG-7652 and LY3015014 are under development.
One RNAi therapeutic, code named ALN-PCS02, is also in devel-
opment [99, 139, 146].
S9: Prolyl oligopeptidase
Enzymes! Peptidases and proteinases! SC: Serine (S) Peptidases! S9: Prolyl oligopeptidase
Nomenclature dipeptidyl-peptidase 4
HGNC, UniProt DPP4, P27487
EC number 3.4.14.5
Endogenous substrates glucagon-like peptide 1 (GCG, P01275)
Inhibitors saxagliptin (pKi 9.2) [184], linagliptin (pKi 9) [122], sitagliptin (pIC50 8.1) [104], vildagliptin (pKi 7.8) [184]
Acetylcholine turnover
Enzymes! Acetylcholine turnover
Overview: Acetylcholine is familiar as a neurotransmitter in the
central nervous system and in the periphery. In the somatic ner-
vous system, it activates nicotinic acetylcholine receptors at the
skeletal neuromuscular junction. It is also employed in the au-
tonomic nervous system, in both parasympathetic and sympa-
thetic branches; in the former, at the smoothmuscle neuromuscu-
lar junction, activating muscarinic acetylcholine receptors. In the
latter, acetylcholine is involved as a neurotransmitter at the gan-
glion, activating nicotinic acetylcholine receptors. Acetylcholine
is synthesised in neurones through the action of choline O-
acetyltransferase and metabolised after release through the extra-
cellular action of acetylcholinesterase and cholinesterase. Choline
is accumulated from the extracellular medium by selective trans-
porters (see SLC5A7 and the SLC44 family). Acetylcholine is ac-
cumulated in synaptic vesicles through the action of the vesicular
acetylcholine transporter SLC18A3.
Searchable database: http://www.guidetopharmacology.org/index.jsp Acetylcholine turnover 6042
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Nomenclature choline O-acetyltransferase acetylcholinesterase (Yt blood group) butyrylcholinesterase
Common abreviation ChAT AChE BChE
HGNC, UniProt CHAT, P28329 ACHE, P22303 BCHE, P06276
EC number 2.3.1.6: acetyl CoA + choline = acetylcholine +
coenzyme A
3.1.1.7: acetylcholine + H2O = acetic acid +
choline + H+
3.1.1.7: acetylcholine + H2O = acetic acid +
choline + H+
Inhibitors – tacrine (pKi 7.5) [52], galantamine (pIC50 6.3)
[87], rivastigmine (pIC50 5.4) [305]
rivastigmine (pIC50 7.4) [305], tacrine (pKi 7.2)
[52]
(Sub)family-selective
inhibitors
– physostigmine (pIC50 7.6–7.8) [305] physostigmine (pIC50 7.6–7.8) [305]
Selective inhibitors – donepezil (pIC50 7.7–8.3) [62, 160, 305],
BW284C51 (pIC50 7.7) [172]
bambuterol (pIC50 8.5) [172]
Comments Splice variants of choline O-acetyltransferase
are suggested to be differentially distributed in
the periphery and CNS (see [28]).
– –
Comments: A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos-oxon, and nerve agents such as tabun,
soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule [505].
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Adenosine turnover
Enzymes! Adenosine turnover
Overview: A multifunctional, ubiquitous molecule, adenosine
acts at cell-surface G protein-coupled receptors, as well as numer-
ous enzymes, including protein kinases and adenylyl cyclase. Ex-
tracellular adenosine is thought to be produced either by export or
by metabolism, predominantly through ecto-5’-nucleotidase ac-
tivity (also producing inorganic phosphate). It is inactivated ei-
ther by extracellular metabolism via adenosine deaminase (also
producing ammonia) or, following uptake by nucleoside trans-
porters, via adenosine deaminase or adenosine kinase (requiring
ATP as co-substrate). Intracellular adenosine may be produced
by cytosolic 5’-nucleotidases or through S-adenosylhomocysteine
hydrolase (also producing L-homocysteine).
Nomenclature Adenosine deaminase Adenosine kinase Ecto-5’-Nucleotidase
S-Adenosylhomocysteine hydrolase
Common
abreviation
ADA ADK NT5E SAHH
HGNC, UniProt ADA, P00813 ADK, P55263 NT5E, P21589 AHCY, P23526
EC number 3.5.4.4: adenosine + H2O = inosine
+ NH3
2.7.1.20 3.1.3.5 3.3.1.1
Endogenous
substrates
– – – S-adenosylhomocysteine
Rank order of
affinity
2’-deoxyadenosine > adenosine adenosine adenosine 5’-monophosphate,
5’-GMP,
5’-inosine monophosphate, 5’-UMP
> 5’-dAMP, 5’-dGMP
–
Products 2’-deoxyinosine, inosine adenosine 5’-monophosphate uridine, inosine, guanine,
adenosine
adenosine
Inhibitors – – – DZNep (pKi 12.3) [174] – Hamster
Selective
inhibitors
pentostatin (pIC50 10.8) [3], EHNA
(pKi 8.8) [3]
A134974 (pIC50 10.2) [325],
ABT702 (pIC50 8.8) [236]
αβ-methyleneADP (pIC50 8.7) [50] 3-deazaadenosine (pIC50 8.5)
[185]
Comments: An extracellular adenosine deaminase activity,
termed ADA2 or adenosine deaminase growth factor (ADGF,
CECR1, Q9NZK5) has been identified [94, 309], which is insen-
sitive to EHNA [546]. Other forms of adenosine deaminase act on
ribonucleic acids and may be divided into two families: ADAT1
(Q9BUB4) deaminates transfer RNA; ADAR (EC 3.5.4.37, also
known as 136 kDa double-stranded RNA-binding protein, P136,
K88DSRBP, Interferon-inducible protein 4); ADARB1 (EC 3.5.-.-, ,
also known as dsRNA adenosine deaminase) and ADARB2 (EC 3.5.-
.-, also known as dsRNA adenosine deaminase B2, RNA-dependent
adenosine deaminase 3) act on double-stranded RNA. Particular
polymorphisms of the ADA gene result in loss-of-function and se-
vere combined immunodeficiency syndrome. Adenosine deami-
nase is able to complex with dipeptidyl peptidase IV (EC 3.4.14.5,
DPP4, also known as T-cell activation antigen CD26, TP103,
adenosine deaminase complexing protein 2) to form a cell-surface
activity [248].
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Amino acid hydroxylases
Enzymes! Amino acid hydroxylases
Overview: The amino acid hydroxylases (monooxygenases), EC.1.14.16.-, are iron-containing enzymes which utilise molecular oxygen and sapropterin as co-substrate and co-factor, respectively. In
humans, as well as in other mammals, there are two distinct L-Tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous
enzymes, TPH1 and TPH2.
Nomenclature L-Phenylalanine hydroxylase L-Tyrosine hydroxylase L-Tryptophan hydroxylase 1 L-Tryptophan hydroxylase 2
HGNC, UniProt PAH, P00439 TH, P07101 TPH1, P17752 TPH2, Q8IWU9
EC number 1.14.16.1: L-phenylalanine + O2 -> L-tyrosine 1.14.16.2: L-tyrosine + O2 ->
levodopa
1.14.16.4 1.14.16.4
Endogenous
activators
Protein kinase A-mediated phosphorylation
(Rat) [1]
Protein kinase A-mediated
phosphorylation [239]
Protein kinase A-mediated
phosphorylation [240]
Protein kinase A-mediated
phosphorylation [240]
Endogenous
substrates
L-phenylalanine L-tyrosine L-tryptophan L-tryptophan
Products L-tyrosine levodopa 5-hydroxy-L-tryptophan 5-hydroxy-L-tryptophan
Cofactors sapropterin sapropterin, Fe2+ – –
Selective
activators
sapropterin (pKi 5.4) [481] – – –
Inhibitors – methyltyrosine – –
Selective
inhibitors
α-methylphenylalanine [180] – Rat, fenclonine α-propyldopacetamide,
3-chlorotyrosine,
3-iodotyrosine,
alpha-methyltyrosine
α-propyldopacetamide,
6-fluorotryptophan [352],
fenclonine, fenfluramine
α-propyldopacetamide,
6-fluorotryptophan [352],
fenclonine, fenfluramine
Comments PAH is an iron bound homodimer or -tetramer
from the same structural family as tyrosine
3-monooxygenase and the tryptophan
hydroxylases. Deficiency or loss-of-function of
PAH is associated with phenylketonuria
TH is a homotetramer, which is
inhibited by dopamine and
other catecholamines in a
physiological negative feedback
pathway [102].
– –
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L-Arginine turnover
Enzymes! L-Arginine turnover
Overview: L-arginine is a basic amino acid with a guanidino
sidechain. As an amino acid, metabolism of L-arginine to form
L-ornithine, catalysed by arginase, forms the last step of the
urea production cycle. L-Ornithine may be utilised as a pre-
cursor of polyamines (see Carboxylases and Decarboxylases) or
recycled via L-argininosuccinic acid to L-arginine. L-Arginine
may itself be decarboxylated to form agmatine, although the
prominence of this pathway in human tissues is uncertain. L-
Arginine may be used as a precursor for guanidoacetic acid for-
mation in the creatine synthesis pathway under the influence of
arginine:glycine amidinotransferase with L-ornithine as a byprod-
uct. Nitric oxide synthase uses L-arginine to generate nitric oxide,
with L-citrulline also as a byproduct.
L-Arginine in proteins may be subject to post-translational mod-
ification through methylation, catalysed by protein arginine
methyltransferases. Subsequent proteolysis can liberate asymmet-
ric NG,NG-dimethyl-L-arginine (ADMA), which is an endogenous
inhibitor of nitric oxide synthase activities. ADMA is hydrol-
ysed by dimethylarginine dimethylhydrolase activities to generate
L-citrulline and dimethylamine.
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Arginase
Enzymes! L-Arginine turnover! Arginase
Overview: Arginase (EC 3.5.3.1) are manganese-containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is
associated more with the kidney.
Comments: N!-hydroxyarginine, an intermediate in NOS metabolism of L-arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform-selective
inhibitors of arginase are not available, examples of inhibitors selective for arginase compared toNOS areN!-hydroxy-nor-L-arginine [483], S-(2-boronoethyl)-L-cysteine [90, 256] and 2(S)-amino-6-boronohexanoic acid
[22, 90].
Arginine:glycine amidinotransferase
Enzymes! L-Arginine turnover! Arginine:glycine amidinotransferase
Nomenclature Arginine:glycine amidinotransferase
Common abreviation AGAT
HGNC, UniProt GATM, P50440
EC number 2.1.4.1
Dimethylarginine dimethylaminohydrolases
Enzymes! L-Arginine turnover! Dimethylarginine dimethylaminohydrolases
Overview: Dimethylarginine dimethylaminohydrolases (DDAH, EC 3.5.3.18) are cytoplasmic enzymes which hydrolyse NG,NG-dimethyl-L-arginine to form dimethylamine and L-citrulline.
Nomenclature NG,NG-Dimethylarginine dimethylaminohydrolase 1 NG,NG-Dimethylarginine dimethylaminohydrolase 2
Common abreviation DDAH1 DDAH2
HGNC, UniProt DDAH1, O94760 DDAH2, O95865
EC number 3.5.3.18 3.5.3.18
Cofactors Zn2+ –
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Nitric oxide synthases
Enzymes! L-Arginine turnover! Nitric oxide synthases
Overview: Nitric oxide synthases (NOS, E.C. 1.14.13.39) utilise
L-arginine (not D-arginine) and molecular oxygen to generate ni-
tric oxide and L-citrulline. The nomenclature suggested by NC-
IUPHAR of NOS I, II and III [340] has not gained wide accep-
tance. eNOS and nNOS isoforms are activated at concentrations
of calcium greater than 100 nM, while iNOS shows higher affinity
for Ca2+/calmodulin (CALM1 CALM2 CALM3, P62158) and thus
appears to be constitutively active. All the three isoforms are ho-
modimers and require sapropterin, flavin adenine dinucleotide,
flavin mononucleotide and NADPH for catalytic activity. L-NAME
is an inhibitor of all three isoforms, with an IC50 value in the mi-
cromolar range.
Nomenclature Endothelial NOS Inducible NOS Neuronal NOS
Common abreviation eNOS iNOS nNOS
HGNC, UniProt NOS3, P29474 NOS2, P35228 NOS1, P29475
EC number 1.14.13.39 1.14.13.39 1.14.13.39
Inhibitors – – N!propyl-L-arginine (pKi 7.2) [548] – Rat
Selective inhibitors – 1400W (pIC50 8.2) [168], 2-amino-4-methylpyridine (pIC50
7.4) [131], PIBTU (pIC50 7.3) [169], NIL (pIC50 5.5) [341],
aminoguanidine [92]
3-bromo-7NI (pIC50 6.1–6.5) [40], 7NI (pIC50 5.3) [19]
Comments: The reductase domain of NOS catalyses the reduction of cytochrome c and other redox-active dyes [322]. NADPH:O2 oxidoreductase catalyses the formation of superoxide anion/H2O2 in
the absence of L-arginine and sapropterin.
Carboxylases and decarboxylases
Enzymes! Carboxylases and decarboxylases
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Carboxylases
Enzymes! Carboxylases and decarboxylases! Carboxylases
Overview: The carboxylases allow the production of new carbon-carbon bonds by introducing HCO3
- or CO2 into target molecules. Two groups of carboxylase activities, some of which are bidirectional,
can be defined on the basis of the cofactor requirement, making use of biotin (EC 6.4.1.-) or vitamin K hydroquinone (EC 4.1.1.-).
Nomenclature Pyruvate carboxylase Acetyl-CoA carboxylase 1 Acetyl-CoA carboxylase 2
Common abreviation PC ACC1 ACC2
HGNC, UniProt PC, P11498 ACACA, Q13085 ACACB, O00763
EC number 6.4.1.1 6.4.1.2 6.4.1.2
Endogenous substrates ATP, pyruvic acid ATP, acetyl CoA acetyl CoA, ATP
Products Pi, adenosine diphosphate, oxalacetic acid Pi, adenosine diphosphate, malonyl-CoA Pi, adenosine diphosphate, malonyl-CoA
Cofactors biotin biotin biotin
Selective inhibitors – TOFA [294] TOFA [294]
Comments – Citrate and other dicarboxylic acids are
allosteric activators of acetyl-CoA carboxylase.
Citrate and other dicarboxylic acids are allosteric
activators of acetyl-CoA carboxylase.
Nomenclature Propionyl-CoA carboxylase γ-Glutamyl carboxylase
Common
abreviation
PCCA, PCCB GGCX
HGNC, UniProt PCCA, P05165 GGCX, P38435
PCCB, P05166
Subunits Propionyl-CoA carboxylase α subunit
Propionyl-CoA carboxylase β subunit
–
EC number 6.4.1.3 4.1.1.90
Endogenous
substrates
propionyl-CoA, ATP glutamyl peptides
Products adenosine diphosphate, methylmalonyl-CoA, Pi carboxyglutamyl peptides
Cofactors biotin vitamin K hydroquinone, NADPH
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(continued)
Nomenclature Propionyl-CoA carboxylase γ-Glutamyl carboxylase
Inhibitors – anisindione
Comments Propionyl-CoA carboxylase is able to function in
both forward and reverse activity modes, as a ligase
(carboxylase) or lyase (decarboxylase), respectively.
Loss-of-function mutations in γ-glutamyl carboxylase are associated with clotting disorders.
Comments: Dicarboxylic acids including citric acid are able to activate ACC1/ACC2 activity allosterically. PCC is able to function in forward and reverse modes as a ligase (carboxylase) or lyase
(decarboxylase) activity, respectively. Loss-of-function mutations in GGCX are associated with clotting disorders.
Decarboxylases
Enzymes! Carboxylases and decarboxylases! Decarboxylases
Overview: The decarboxylases generate CO2 and the indicated products from acidic substrates, requiring pyridoxal phosphate or pyruvic acid as a co-factor.
Nomenclature S-Adenosylmethionine L-Arginine L-Aromatic amino-acid Glutamic acid Glutamic acid
decarboxylase decarboxylase decarboxylase decarboxylase 1 decarboxylase 2
Common
abreviation
SAMDC ADC AADC GAD1 GAD2
HGNC, UniProt AMD1, P17707 AZIN2, Q96A70 DDC, P20711 GAD1, Q99259 GAD2, Q05329
EC number 4.1.1.50 4.1.1.19 4.1.1.28: levodopa ->
dopamine + CO2
5-hydroxy-L-tryptophan
-> 5-hydroxytryptamine
+ CO2 This enzyme also
catalyses the following
reaction:: L-tryptophan
-> tryptamine + CO2
4.1.1.15: L-glutamic acid
+ H+ -> GABA + CO2
4.1.1.15: L-glutamic acid +
H+ -> GABA + CO2
Substrates – – Deuterium-substituted – –
L-DOPA [312]
Endogenous
substrates
S-adenosyl methionine L-arginine levodopa,
5-hydroxy-L-tryptophan,
L-tryptophan
L-glutamic acid,
L-aspartic acid
L-glutamic acid,
L-aspartic acid
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(continued)
Nomenclature S-Adenosylmethionine L-Arginine L-Aromatic amino-acid Glutamic acid Glutamic acid
decarboxylase decarboxylase decarboxylase 1 decarboxylase 2
Products S-adenosyl-L- agmatine [552] 5-hydroxytryptamine, GABA GABA
methioninamine dopamine
Cofactors pyruvic acid pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate
Selective
inhibitors
sardomozide (pIC50 8)
[455]
–
3-hydroxybenzylhydrazine,
L-α-methyldopa,
benserazide [101],
carbidopa
s-allylglycine s-allylglycine
Comments s-allylglycine is also an
inhibitor of SAMDC
[368].
The presence of a
functional ADC activity in
human tissues has been
questioned [89].
AADC is a homodimer. L-aspartic acid is a less
rapidly metabolised
substrate of mouse brain
glutamic acid
decarboxylase generating
β-alanine [530].
Autoantibodies against
GAD1 and GAD2 are
elevated in type 1
diabetes mellitus and
neurological disorders
(see Further reading).
L-aspartic acid is a less rapidly
metabolised substrate of
mouse brain glutamic acid
decarboxylase generating
β-alanine [530].
Autoantibodies against GAD1
and GAD2 are elevated in
type 1 diabetes mellitus and
neurological disorders (see
Further reading).
Nomenclature Histidine decarboxylase Malonyl-CoA decarboxylase Ornithine decarboxylase Phosphatidylserine decarboxylase
Common
abreviation
HDC MLYCD ODC PSDC
HGNC, UniProt HDC, P19113 MLYCD, O95822 ODC1, P11926 PISD, Q9UG56
EC number 4.1.1.22 4.1.1.9 4.1.1.17 4.1.1.65
Endogenous
substrates
L-histidine malonyl-CoA L-ornithine phosphatidylserine
Products histamine acetyl CoA putrescine phosphatidylethanolamine
Cofactors pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate pyruvic acid
Selective
inhibitors
AMA, FMH [164] – APA (pIC50 7.5) [456],
eflornithine (pKd 4.9) [394]
–
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Nomenclature Histidine decarboxylase Malonyl-CoA decarboxylase Ornithine decarboxylase Phosphatidylserine decarboxylase
Comments – Inhibited by AMP-activated
protein kinase-evoked
phosphorylation [415]
The activity of ODC is regulated
by the presence of an antizyme
(ENSG00000104904) and an
ODC antizyme inhibitor
(ENSG00000155096).
S-allylglycine is also an inhibitor of
SAMDC [368].
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Catecholamine turnover
Enzymes! Catecholamine turnover
Overview: Catecholamines are defined by the presence of
two adjacent hydroxyls on a benzene ring with a sidechain
containing an amine. The predominant catacholamines
in mammalian biology are the neurotransmitter/hormones
dopamine, (-)-noradrenaline (norepinephrine) and (-)-adrenaline
(epinephrine). These hormone/transmitters are synthe-
sized by sequential metabolism from L-phenylalanine via
L-tyrosine. Hydroxylation of L-tyrosine generates levodopa,
which is decarboxylated to form dopamine. Hydroxylation
of the ethylamine sidechain generates (-)-noradrenaline (nore-
pinephrine), which can be methylated to form (-)-adrenaline
(epinephrine). In particular neuronal and adrenal chromaf-
fin cells, the catecholamines dopamine, (-)-noradrenaline and
(-)-adrenaline are accumulated into vesicles under the influence
of the vesicular monoamine transporters (VMAT1/SLC18A1 and
VMAT2/SLC18A2). After release into the synapse or the blood-
stream, catecholamines are accumulated through the action
cell-surface transporters, primarily the dopamine (DAT/SLC6A3)
and norepinephrine transporter (NET/SLC6A2). The primary
routes of metabolism of these catecholamines are oxidation via
monoamine oxidase activities of methylation via catechol O-
methyltransferase.
Nomenclature L-Phenylalanine hydroxylase Tyrosine aminotransferase L-Aromatic amino-acid decarboxylase
Common abreviation – TAT AADC
HGNC, UniProt PAH, P00439 TAT, P17735 DDC, P20711
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Nomenclature L-Phenylalanine hydroxylase Tyrosine aminotransferase L-Aromatic amino-acid decarboxylase
EC number 1.14.16.1: L-phenylalanine + O2 -> L-tyrosine 2.6.1.5: L-tyrosine + α-ketoglutaric acid ->
4-hydroxyphenylpyruvic acid + L-glutamic acid
4.1.1.28: levodopa -> dopamine + CO2
5-hydroxy-L-tryptophan -> 5-hydroxytryptamine
+ CO2 This enzyme also catalyses the following
reaction:: L-tryptophan -> tryptamine + CO2
Endogenous activators Protein kinase A-mediated phosphorylation
(Rat) [1]
– –
Substrates – – Deuterium-substituted L-DOPA [312]
Endogenous substrates L-phenylalanine – levodopa, 5-hydroxy-L-tryptophan, L-tryptophan
Products L-tyrosine – 5-hydroxytryptamine, dopamine
Cofactors sapropterin pyridoxal phosphate pyridoxal phosphate
Selective activators sapropterin (pKi 5.4) [481] – –
Selective inhibitors α-methylphenylalanine [180] – Rat, fenclonine – 3-hydroxybenzylhydrazine, L-α-methyldopa,
benserazide [101], carbidopa
Comments PAH is an iron bound homodimer or -tetramer
from the same structural family as tyrosine
3-monooxygenase and the tryptophan
hydroxylases. Deficiency or loss-of-function of
PAH is associated with phenylketonuria
Tyrosine may also be metabolized in the liver
by tyrosine transaminase to generate
4-hydroxyphenylpyruvic acid, which can be
further metabolized to homogentisic acid.
TAT is a homodimer, where loss-of-function
mutations are associated with
type II tyrosinemia.
AADC is a homodimer.
Nomenclature L-Tyrosine hydroxylase Dopamine beta-hydroxylase Phenylethanolamine N-methyltransferase
(dopamine beta-monooxygenase)
Common abreviation – DBH PNMT
HGNC, UniProt TH, P07101 DBH, P09172 PNMT, P11086
EC number 1.14.16.2: L-tyrosine + O2 -> levodopa 1.14.17.1: dopamine + O2 = (-)-noradrenaline
+ H2O
2.1.1.28: (-)-noradrenaline -> (-)-adrenaline
Endogenous activators Protein kinase A-mediated phosphorylation
[239]
– –
Endogenous substrates L-tyrosine – –
Products levodopa – –
Cofactors sapropterin, Fe2+ Cu2+, L-ascorbic acid S-adenosyl methionine
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Nomenclature L-Tyrosine hydroxylase Dopamine beta-hydroxylase Phenylethanolamine N-methyltransferase
(dopamine beta-monooxygenase)
Inhibitors methyltyrosine nepicastat (pIC50 8) [458] LY134046 (pKi 7.6) [154]
Selective inhibitors α-propyldopacetamide, 3-chlorotyrosine,
3-iodotyrosine, alpha-methyltyrosine
– –
Comments TH is a homotetramer, which is inhibited by
dopamine and other catecholamines in a
physiological negative feedback pathway
[102].
DBH is a homotetramer.
A protein structurally-related to DBH (MOXD1,
Q6UVY6) has been described and for which a
function has yet to be identified [71].
–
Nomenclature Monoamine oxidase A Monoamine oxidase B Catechol-O-methyltransferase
Common abreviation MAO-A MAO-B COMT
HGNC, UniProt MAOA, P21397 MAOB, P27338 COMT, P21964
EC number 1.4.3.4 (-)-adrenaline ->
3,4-dihydroxymandelic acid + NH3
(-)-noradrenaline ->
3,4-dihydroxymandelic acid + NH3 tyramine
-> 4-hydroxyphenyl acetaldehyde + NH3
dopamine ->
3,4-dihydroxyphenylacetaldehyde + NH3
5-hydroxytryptamine ->
5-hydroxyindole acetaldehyde + NH3
1.4.3.4 2.1.1.6: S-adenosyl-L-methionine + a catechol =
S-adenosyl-L-homocysteine + a guaiacol
(-)-noradrenaline -> normetanephrine dopamine
-> 3-methoxytyramine
3,4-dihydroxymandelic acid ->
vanillylmandelic acid (-)-adrenaline ->
metanephrine
Cofactors flavin adenine dinucleotide flavin adenine dinucleotide S-adenosyl methionine
Inhibitors moclobemide (pKi 8.3) [234], phenelzine
(Irreversible inhibition) (pKi 7.3) [36],
tranylcypromine (pIC50 4.7) [538], selegiline
(pKi 4.2) [333], befloxatone [100], clorgiline,
pirlindole [327]
rasagiline (pIC50 7.8) [542], phenelzine
(Irreversible inhibition) (pKi 7.8) [36],
lazabemide (pKi 7.1) [188, 489], selegiline
(pKi 5.7–6) [113, 333], tranylcypromine
(pIC50 4.7) [538]
tolcapone (soluble enzyme) (pKi 9.6) [299],
tolcapone (membrane-bound enzyme) (pKi 9.5)
[299], entacapone (soluble enzyme) (pKi 9.5)
[299], entacapone (membrane-bound enzyme)
(pKi 8.7) [299]
Selective inhibitors – safinamide (pKi 6.3) [35] –
Comments – – COMT appears to exist in both membrane-bound
and soluble forms. COMT has also been described
to methylate steroids, particularly
hydroxyestradiols
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Ceramide turnover
Enzymes! Ceramide turnover
Overview: Ceramides are a family of sphingophospholipids syn-
thesized in the endoplasmic reticulum, which mediate cell stress
responses, including apoptosis, autophagy and senescence, Ser-
ine palmitoyltransferase generates 3-ketosphinganine, which is re-
duced to sphinganine (dihydrosphingosine). N-Acylation allows
the formation of dihydroceramides, which are subsequently re-
duced to form ceramides. Once synthesized, ceramides are traf-
ficked from the ER to theGolgi bound to the ceramide transfer pro-
tein, CERT (COL4A3BP, Q9Y5P4). Ceramide can be metabolized
via multiple routes, ensuring tight regulation of its cellular lev-
els. Addition of phosphocholine generates sphingomyelin while
carbohydrate is added to form glucosyl- or galactosylceramides.
Ceramidase re-forms sphingosine or sphinganine from ceramide
or dihydroceramide. Phosphorylation of ceramide generates ce-
ramide phosphate. The determination of accurate kinetic param-
eters for many of the enzymes in the sphingolipid metabolic path-
way is complicated by the lipophilic nature of the substrates.
Serine palmitoyltransferase
Enzymes! Ceramide turnover! Serine palmitoyltransferase
Overview: The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic
activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb weremost active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA [190]. Complexes
involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar activity with
C16, C18 and C20 acylCoAs [190].
Nomenclature serine palmitoyltransferase, serine palmitoyltransferase,
serine palmitoyltransferase, serine palmitoyltransferase, serine palmitoyltransferase,
long chain base subunit 1 long chain base subunit 2 long chain base subunit 3 small subunit A small subunit B
Common
abreviation
SPT1 SPT2 SPT3 SPTSSA SPTSSB
HGNC,
UniProt
SPTLC1, O15269 SPTLC2, O15270 SPTLC3, Q9NUV7 SPTSSA, Q969W0 SPTSSB, Q8NFR3
Searchable database: http://www.guidetopharmacology.org/index.jsp Serine palmitoyltransferase 6055
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(continued)
Nomenclature serine palmitoyltransferase, serine palmitoyltransferase,
serine palmitoyltransferase, serine palmitoyltransferase, serine palmitoyltransferase,
long chain base subunit 1 long chain base subunit 2 long chain base subunit 3 small subunit A small subunit B
EC number 2.3.1.50: L-serine + 2.3.1.50: L-serine + 2.3.1.50: L-serine + – –
palmitoyl-CoA -> palmitoyl-CoA -> palmitoyl-CoA ->
3-ketosphinganine + 3-ketosphinganine + 3-ketosphinganine +
coenzyme A + CO2 coenzyme A CO2 + coenzyme A CO2 +
Cofactors pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate – –
Selective
inhibitors
myriocin [334] myriocin [334] myriocin [334] – –
Ceramide synthase
Enzymes! Ceramide turnover! Ceramide synthase
Overview: This family of enzymes, also known as sphingosine N-acyltransferase, is located in the ER facing the cytosol with an as-yet undefined topology and stoichiometry. Ceramide synthase in vitro
is sensitive to inhibition by the fungal derived toxin, fumonisin B1.
Nomenclature ceramide synthase 1 ceramide synthase 2 ceramide synthase 3
Common abreviation CERS1 CERS2 CERS3
HGNC, UniProt CERS1, P27544 CERS2, Q96G23 CERS3, Q8IU89
EC number 2.3.1.24: acylCoA + sphinganine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA -> ceramide +
coenzyme A
2.3.1.24: acylCoA + sphinganine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA -> ceramide +
coenzyme A
2.3.1.24: acylCoA + sphinganine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA -> ceramide + coenzyme A
Substrates C18-CoA [499] C24- and C26-CoA [278] C26-CoA and longer [337, 396]
Searchable database: http://www.guidetopharmacology.org/index.jsp Ceramide synthase 6056
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Nomenclature ceramide synthase 4 ceramide synthase 5 ceramide synthase 6
Common abreviation CERS4 CERS5 CERS6
HGNC, UniProt CERS4, Q9HA82 CERS5, Q8N5B7 CERS6, Q6ZMG9
EC number 2.3.1.24: acylCoA + sphinganine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA -> ceramide +
coenzyme A
2.3.1.24: acylCoA + sphinganine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA -> ceramide +
coenzyme A
2.3.1.24: acylCoA + sphinganine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA -> ceramide + coenzyme A
Substrates C18-, C20- and C22-CoA [405] C16-CoA [274, 405] C14- and C16-CoA [336]
Sphingolipid 14-desaturase
Enzymes! Ceramide turnover! Sphingolipid 14-desaturase
Overview: DEGS1 and DEGS2 are 4TM proteins.
Nomenclature delta(4)-desaturase, sphingolipid 1 delta(4)-desaturase, sphingolipid 2
HGNC, UniProt DEGS1, O15121 DEGS2, Q6QHC5
EC number 1.14.-.- 1.14.-.-
Cofactors NAD NAD
Comments Myristoylation of DEGS1 enhances its activity and targets it to the mitochondria [26]. –
Comments: DEGS1 activity is inhibited by a number of natural products, including curcumin and 19-tetrahydrocannabinol [130].
Searchable database: http://www.guidetopharmacology.org/index.jsp Sphingolipid 14-desaturase 6057
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Sphingomyelin synthase
Enzymes! Ceramide turnover! Sphingomyelin synthase
Overview: Following translocation from the ER to the Golgi under the influence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of
phosphocholine from the phospholipid phosphatidylcholine.
Sphingomyelin synthase-related protein 1 is structurally related but lacks sphingomyelin synthase activity.
Nomenclature sphingomyelin synthase 1 sphingomyelin synthase 2 sterile alpha motif domain containing 8
HGNC, UniProt SGMS1, Q86VZ5 SGMS2, Q8NHU3 SAMD8, Q96LT4
EC number 2.7.8.27: ceramide + phosphatidylcholine ->
sphingomyelin + diacylglycerol
2.7.8.27: ceramide + phosphatidylcholine ->
sphingomyelin + diacylglycerol
2.7.8.-: ceramide + phosphatidylethanolamine ->
ceramide phosphoethanolamine
Comments – Palmitoylation of sphingomyelin synthase 2
may allow targeting to the plasma membrane
[476].
–
Sphingomyelin phosphodiesterase
Enzymes! Ceramide turnover! Sphingomyelin phosphodiesterase
Overview: Also known as sphingomyelinase.
Nomenclature sphingomyelin phosphodiesterase 1, sphingomyelin phosphodiesterase 2, sphingomyelin phosphodiesterase 3,
acid lysosomal neutral membrane (neutral sphingomyelinase) neutral membrane (neutral sphingomyelinase II)
HGNC, UniProt SMPD1, P17405 SMPD2, O60906 SMPD3, Q9NY59
EC number 3.1.4.12: sphingomyelin -> ceramide +
phosphocholine
3.1.4.12: sphingomyelin -> ceramide +
phosphocholine
3.1.4.12: sphingomyelin -> ceramide +
phosphocholine
Searchable database: http://www.guidetopharmacology.org/index.jsp Sphingomyelin phosphodiesterase 6058
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Nomenclature sphingomyelin phosphodiesterase 4, neutral sphingomyelin phosphodiesterase, acid-like 3A sphingomyelin phosphodiesterase, acid-like 3B
membrane (neutral sphingomyelinase-3)
HGNC, UniProt SMPD4, Q9NXE4 SMPDL3A, Q92484 SMPDL3B, Q92485
EC number 3.1.4.12: sphingomyelin -> ceramide +
phosphocholine
3.1.4.-: sphingomyelin -> ceramide +
phosphocholine
3.1.4.-: sphingomyelin -> ceramide +
phosphocholine
Neutral sphingomyelinase coupling factors
Enzymes! Ceramide turnover! Neutral sphingomyelinase coupling factors
Overview: Protein FAN [2] and polycomb protein EED [383] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.
Nomenclature embryonic ectoderm development neutral sphingomyelinase (N-SMase) activation associated factor
HGNC, UniProt EED, O75530 NSMAF, Q92636
Ceramide glucosyltransferase
Enzymes! Ceramide turnover! Ceramide glucosyltransferase
Nomenclature UDP-glucose ceramide glucosyltransferase
HGNC, UniProt UGCG, Q16739
EC number 2.4.1.80: UDP-glucose + ceramide = uridine diphosphate + glucosylceramide
Inhibitors miglustat (pKi 5.1) [53]
Comments Glycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains.
Searchable database: http://www.guidetopharmacology.org/index.jsp Ceramide glucosyltransferase 6059
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Acid ceramidase
Enzymes! Ceramide turnover! Acid ceramidase
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase (acid ceramidase) 1
HGNC, UniProt ASAH1, Q13510
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid
Comments This lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product [261].
Neutral ceramidases
Enzymes! Ceramide turnover! Neutral ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2B
HGNC, UniProt ASAH2, Q9NR71 ASAH2B, P0C7U1
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid –
Comments The enzyme is associated with the plasma membrane [475]. –
Comments: ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.
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Alkaline ceramidases
Enzymes! Ceramide turnover! Alkaline ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature alkaline ceramidase 1 alkaline ceramidase 2 alkaline ceramidase 3
HGNC, UniProt ACER1, Q8TDN7 ACER2, Q5QJU3 ACER3, Q9NUN7
EC number 3.5.1.23: ceramide -> sphingosine + a fatty
acid
3.5.1.23: ceramide -> sphingosine + a fatty acid 3.5.1.-
Comments ACER1 is associated with the ER [466]. ACER2 is associated with the Golgi apparatus [534]. ACER3 is associated with the ER and Golgi
apparatus [314].
Ceramide kinase
Enzymes! Ceramide turnover! Ceramide kinase
Nomenclature ceramide kinase
HGNC, UniProt CERK, Q8TCT0
EC number 2.7.1.138: ceramide + ATP -> ceramide 1-phosphate + adenosine diphosphate
Inhibitors NVP 231 (pIC50 7.9) [178]
Comments: A ceramide kinase-like protein has been identified in the human genome (CERKL, Q49MI3).
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Chromatin modifying enzymes
Enzymes! Chromatin modifying enzymes
Overview: Chromatin modifying enzymes, and other
chromatin-modifying proteins, fall into three broad categories:
writers, readers and erasers. The function of these pro-
teins is to dynamically maintain cell identity and regulate pro-
cesses such as differentiation, development, proliferation and
genome integrity via recognition of specific ’marks’ (covalent
post-translational modifications) on histone proteins and DNA
[267]. In normal cells, tissues and organs, precise co-ordination
of these proteins ensures expression of only those genes required
to specify phenotype or which are required at specific times, for
specific functions. Chromatin modifications allow DNA modifi-
cations not coded by the DNA sequence to be passed on through
the genome and underlies heritable phenomena such as X chro-
mosome inactivation, aging, heterochromatin formation, repro-
gramming, and gene silencing (epigenetic control).
To date at least eight distinct types of modifications are found
on histones. These include small covalent modifications such as
acetylation, methylation, and phosphorylation, the attachment
of larger modifiers such as ubiquitination or sumoylation, and
ADP ribosylation, proline isomerization and deimination. Chro-
matin modifications and the functions they regulate in cells are
reviewed by Kouzarides (2007) [267].
Writer proteins include the histone methyltransferases, histone
acetyltransferases, some kinases and ubiquitin ligases.
Readers include proteins which contain methyl-lysine-
recognition motifs such as bromodomains, chromodomains,
tudor domains, PHD zinc fingers, PWWP domains and MBT
domains.
Erasers include the histone demethylases and histone deacety-
lases (HDACs and sirtuins).
Dysregulated epigenetic control can be associated with human dis-
eases such as cancer [129], where a wide variety of cellular and pro-
tein abberations are known to perturb chromatin structure, gene
transcription and ultimately cellular pathways [24, 439]. Due to
the reversible nature of epigenetic modifications, chromatin reg-
ulators are very tractable targets for drug discovery and the devel-
opment of novel therapeutics. Indeed, small molecule inhibitors
of writers (e.g. azacitidine and decitabine target the DNA methyl-
transferases DNMT1 and DNMT3 for the treatment of myelodys-
plastic syndromes [165, 520]) and erasers (e.g. the HDAC in-
hibitors vorinostat, romidepsin and belinostat for the treatment of
T-cell lymphomas [144, 254]) are already being used in the clinic.
The search for the next generation of compounds with improved
specificity against chromatin-associated proteins is an area of in-
tense basic and clinical research [56]. Current progress in this field
is reviewed by Simó-Riudalbas and Esteller (2015) [440].
2.1.1.- Protein arginine N-methyltransferases
Enzymes! Chromatin modifying enzymes! 2.1.1.- Protein arginine N-methyltransferases
Overview: Protein arginine N-methyltransferases (PRMT,
EC 2.1.1.-) encompass histone arginine N-methyltransferases
(PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein N-
methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric
or tetrameric enzymes which use S-adenosyl methionine as
a methyl donor, generating S-adenosylhomocysteine as a
by-product. They generate both mono-methylated and di-
methylated products; these may be symmetric (SDMA) or asym-
metric (NG,NG-dimethyl-L-arginine) versions, where both guani-
dine nitrogens are monomethylated or one of the two is dimethy-
lated, respectively.
3.5.1.- Histone deacetylases (HDACs)
Enzymes! Chromatin modifying enzymes! 3.5.1.- Histone deacetylases (HDACs)
Overview: Histone deacetylases act as erasers of epigenetic acety-
lation marks on lysine residues in histones. Removal of the acetyl
groups facilitates tighter packing of chromatin (heterochromatin
formation) leading to transcriptional repression.
The histone deacetylase family has been classified in to five sub-
families based on phylogenetic comparison with yeast homo-
logues:
Class I contains HDACs 1, 2, 3 and 8
Class IIa contains HDACs 4, 5, 7 and 9
Class IIb contains HDACs 6 and 10
Class III contains the sirtuins (SIRT1-7)
Class IV contains only HDAC11.
Classes I, II and IV use Zn+ as a co-factor, whereas catalysis by
Class III enzymes requires NAD+ as a co-factor, and members of
this subfamily have ADP-ribosylase activity in addition to protein
deacetylase function [420].
HDACs have more general protein deacetylase activity, being able
to deacetylate lysine residues in non-histone proteins [82] such as
microtubules [221], the hsp90 chaperone [268] and the tumour
suppressor p53 [302].
DysregulatedHDAC activity has been identified in cancer cells and
tumour tissues [288, 410], making HDACs attractive molecular
targets in the search for novel mechanisms to treat cancer [522].
Several small molecule HDAC inhibitors are already approved
for clinical use: romidepsin, belinostat, vorinostat, panobinostat,
belinostat, valproic acid and chidamide. HDACs and HDAC in-
hibitors currently in development as potential anti-cancer thera-
peutics are reviewed by Simó-Riudalbas and Esteller (2015) [440].
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Cyclic nucleotide turnover
Enzymes! Cyclic nucleotide turnover
Overview: Cyclic nucleotides are second messengers generated by cyclase enzymes from precursor triphosphates and hydrolysed by phosphodiesterases. The cellular actions of these cyclic nucleotides
are mediated through activation of protein kinases (cAMP- and cGMP-dependent protein kinases), ion channels (cyclic nucleotide-gated, CNG, and hyperpolarization and cyclic nucleotide-gated, HCN)
and guanine nucleotide exchange factors (GEFs, Epac).
Adenylyl cyclases
Enzymes! Cyclic nucleotide turnover! Adenylyl cyclases
Overview: Adenylyl cyclase, E.C. 4.6.1.1, converts ATP to
cyclic AMP and pyrophosphate. Mammalian membrane-bound
adenylyl cyclases are typically made up of two clusters of
six TM domains separating two intracellular, overlapping cat-
alytic domains that are the target for the nonselective activa-
tors forskolin, NKH477 (except AC9, [392]) and Gαs (the stim-
ulatory G protein α subunit). Adenosine and its derivatives
(e.g. 2’,5’-dideoxyadenosine), acting through the P-site, appear
to be physiological inhibitors of adenylyl cyclase activity [485].
Three families of adenylyl cyclase are distinguishable: calmodulin
(CALM1 CALM2 CALM3, P62158)-stimulated (AC1, AC3 and
AC8), Ca2+-inhibitable (AC5, AC6 and AC9) and Ca2+-insensitive
(AC2, AC4 and AC7) forms.
Nomenclature AC1 AC2 AC3 AC4 AC5
HGNC,
UniProt
ADCY1, Q08828 ADCY2, Q08462 ADCY3, O60266 ADCY4, Q8NFM4 ADCY5, O95622
EC number 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1
Endogenous
activators
calmodulin (CALM1 CALM2
CALM3, P62158),
PKC-evoked
phosphorylation [233,
474]
Gβγ, PKC-evoked
phosphorylation [73, 306,
478]
calmodulin (CALM1 CALM2
CALM3, P62158),
PKC-evoked
phosphorylation [81, 233]
Gβγ [163] PKC-evoked
phophorylation [250]
Endogenous
inhibitors
Gαi, Gαo, Gβγ [478, 479] – Gαi, RGS2, CaM kinase
II-evoked phosphorylation
[441, 479, 517]
PKC-evoked
phophorylation [554]
Gαi, Ca
2+, PKA-evoked
phosphorylation [227,
230, 479]
Selective
inhibitors
– – – – NKY80 [364]
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Nomenclature AC6 AC7 AC8 AC9
HGNC, UniProt ADCY6, O43306 ADCY7, P51828 ADCY8, P40145 ADCY9, O60503
EC number 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1
Endogenous
activators
– PKC-evoked phosphorylation [516] Ca2+ [57] –
Endogenous
inhibitors
Gαi, Ca
2+, PKA-evoked
phosphorylation, PKC-evoked
phosphorylation [76, 275, 479,
541]
– – Ca2+/calcineurin [376]
Comments: Nitric oxide has been proposed to inhibit AC5 and AC6 selectively [210], although it is unclear whether this phenomenon is of physiological significance. A soluble adenylyl cyclase has
been described (ADCY10, Q96PN6 [48]), unaffected by either Gα or Gβγ subunits, which has been suggested to be a cytoplasmic bicarbonate (pH-insensitive) sensor [75]. It can be inhibited selectively by
KH7 (pIC50 5.0-5.5) [208].
Soluble guanylyl cyclase
Enzymes! Cyclic nucleotide turnover! Soluble guanylyl cyclase
Overview: Soluble guanylyl cyclase (GTP diphosphate-lyase (cyclising)), E.C. 4.6.1.2, is a heterodimer comprising α and β chains, both of which have two subtypes in man (predominantly α1β1; [544]).
A haem group is associated with the β chain and is the target for the endogenous ligand nitric oxide (NO), and, potentially, carbon monoxide [150]. The enzyme converts guanosine-5’-triphosphate to
the intracellular second messenger 3’,5’-guanosine monophosphate (cyclic GMP).
Nomenclature Soluble guanylyl cyclase
Common abreviation sGC
Subunits Soluble guanylyl cyclase β 1 subunit, Soluble guanylyl cyclase α 1 subunit
EC number 4.6.1.2
Activators isosorbide dinitrate, isosorbide mononitrate, nitroglycerin
Selective activators BAY412272 [460], NO, YC1 [150], ataciguat [421], cinaciguat [461], riociguat [461]
Inhibitors NS 2028 (pIC50 8.1) [363] – Bovine
Selective inhibitors ODQ (pIC50 7.5) [167]
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Subunits
Nomenclature α 1 subunit α 2 subunit β 1 subunit β 2 subunit
HGNC, UniProt GUCY1A3, Q02108 GUCY1A2, P33402 GUCY1B3, Q02153 GUCY1B2, O75343
Comments: ODQ also shows activity at other haem-containing proteins [134], while YC1 may also inhibit cGMP-hydrolysing phosphodiesterases [149, 159].
Exchange protein activated by cyclic AMP (Epac)
Enzymes! Cyclic nucleotide turnover! Exchange protein activated by cyclic AMP (Epac)
Overview: Epacs are members of a family of guanine nu-
cleotide exchange factors (ENSFM00250000000899), which also
includes RapGEF5 (GFR, KIAA0277, MR-GEF, Q92565) and
RapGEFL1 (Link-GEFII, Q9UHV5). They are activated endoge-
nously by cyclic AMP and with some pharmacological selectiv-
ity by 8-pCPT-2’-O-Me-cAMP [126]. Once activated, Epacs in-
duce an enhanced activity of the monomeric G proteins, Rap1
and Rap2 by facilitating binding of guanosine-5’-triphosphate
in place of guanosine 5’-diphosphate, leading to activation of
phospholipase C [423].
Nomenclature Epac1 Epac2
HGNC, UniProt RAPGEF3, O95398 RAPGEF4, Q8WZA2
Inhibitors – HJC 0350 (pIC50 6.5) [72], ESI-09 (pIC50 4.4) [11]
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Phosphodiesterases, 3’,5’-cyclic nucleotide
Enzymes! Cyclic nucleotide turnover! Phosphodiesterases, 3’,5’-cyclic nucleotide
Overview: 3’,5’-Cyclic nucleotide phosphodiesterases (PDEs, 3’,5’-cyclic-nucleotide 5’-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3’,5’-cyclic nucleotide (usually cyclic AMP or
cyclic GMP). Isobutylmethylxanthine is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2’,3’-cyclic nucleotide 3’-phosphodiesterase
(E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.
Nomenclature PDE1A PDE1B PDE1C
HGNC, UniProt PDE1A, P54750 PDE1B, Q01064 PDE1C, Q14123
EC number 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic GMP > cyclic AMP cyclic GMP > cyclic AMP cyclic GMP = cyclic AMP
Endogenous activators calmodulin (CALM1 CALM2
CALM3, P62158)
calmodulin (CALM1 CALM2
CALM3, P62158)
calmodulin (CALM1 CALM2 CALM3, P62158)
Selective inhibitors SCH51866 (pIC50 7.2) [498],
vinpocetine (pIC50 5.1) [300]
SCH51866 (pIC50 7.2) [498] SCH51866 (pIC50 7.2) [498], vinpocetine (pIC50 4.3) [300]
Nomenclature PDE2A PDE3A PDE3B
HGNC, UniProt PDE2A, O00408 PDE3A, Q14432 PDE3B, Q13370
EC number 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic AMP cyclic GMP – –
Endogenous activators cyclic GMP – –
Endogenous inhibitors – cyclic GMP (Selective) cyclic GMP (Selective)
Inhibitors milrinone (pIC50 <6.5) [465] cilostazol (pIC50 6.7) [465], inamrinone
(pIC50 4.8) [442]
–
Selective inhibitors BAY607550 (pIC50 8.3–8.8) [44], EHNA
(pIC50 5.3) [332]
cilostamide (pIC50 7.5) [465], anagrelide
(pIC50 7.1–7.3) [245, 319, 326], milrinone
(pIC50 6.3–6.4) [123, 465]
cilostamide (pIC50 7.3) [465], cilostazol (pIC50 6.4) [465],
milrinone (pIC50 6) [465], inamrinone (pIC50 4.5) [465]
Comments EHNA is also an inhibitor of
adenosine deaminase (E.C. 3.5.4.4).
– –
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Nomenclature PDE4A PDE4B PDE4C PDE4D PDE5A
HGNC,
UniProt
PDE4A, P27815 PDE4B, Q07343 PDE4C, Q08493 PDE4D, Q08499 PDE5A, O76074
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Activator – – – PKA-mediated
phosphorylation [217]
Protein kinase A, protein kinase
G [93]
Rank order of
affinity
cyclic AMP cyclic GMP cyclic AMP cyclic GMP cyclic AMP cyclic GMP cyclic AMP cyclic GMP cyclic GMP > cyclic AMP
Inhibitors ibudilast (pIC50 7.3)
[262], RS-25344 (pIC50
7.2) [417]
roflumilast (pIC50 9.4)
[301], ibudilast (pIC50
7.2) [262], RS-25344
(pIC50 6.5) [417]
RS-25344 (pIC50 8.1)
[417], ibudilast (pIC50
6.6) [262]
RS-25344 (pIC50 8.4)
[417]
gisadenafil (pIC50 8.9) [402],
milrinone (pIC50 7.3)
(Sub)family-
selective
inhibitors
rolipram (pIC50 9) [508],
Ro20-1724 (pIC50 6.5)
[508]
rolipram (pIC50 9) [508],
Ro20-1724 (pIC50 6.4)
[508]
rolipram (pIC50 6.5)
[508], Ro20-1724 (pIC50
5.4) [508]
rolipram (pIC50 7.2)
[508], Ro20-1724 (pIC50
6.2) [508]
–
Selective
inhibitors
YM976 (pIC50 8.3) [13] – – – vardenafil (pIC50 9.7) [47],
T0156 (pIC50 9.5) [338],
sildenafil (pIC50 9) [494],
tadalafil (pIC50 8.5) [339],
SCH51866 (pIC50 7.2) [498],
zaprinast (pIC50 6.8) [494]
Nomenclature PDE6A PDE6B PDE6C PDE6D PDE6G PDE6H
HGNC, UniProt PDE6A, P16499 PDE6B, P35913 PDE6C, P51160 PDE6D, O43924 PDE6G, P18545 PDE6H, Q13956
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Nomenclature PDE7A PDE7B PDE8A PDE8B
HGNC, UniProt PDE7A, Q13946 PDE7B, Q9NP56 PDE8A, O60658 PDE8B, O95263
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic AMP cyclic GMP
[330]
cyclic AMP cyclic GMP
[166]
cyclic AMP cyclic GMP [138] cyclic AMP cyclic GMP [201]
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Nomenclature PDE7A PDE7B PDE8A PDE8B
Inhibitors – BRL50481 (pIC50 4.9) [7] – –
Selective inhibitors BRL50481 (pIC50
6.7–6.8) [7, 448]
dipyridamole (pIC50
5.7–6) [166, 419],
SCH51866 (pIC50 5.8)
[419]
dipyridamole (pIC50 5.1) [138] dipyridamole (pIC50 4.3) [201]
Comments – – PDE7A appears to be membrane-bound or
soluble for PDE7A1 and 7A2 splice
variants, respectively
–
Nomenclature PDE9A PDE10A PDE11A
HGNC, UniProt PDE9A, O76083 PDE10A, Q9Y233 PDE11A, Q9HCR9
EC number 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic GMP cyclic AMP [137] cyclic AMP, cyclic GMP [152] cyclic AMP, cyclic GMP [133]
Inhibitors – – tadalafil (pIC50 6.5) [339], BC11-38 (pIC50 6.5) [68]
Selective inhibitors SCH51866 (pIC50 5.8) [137],
zaprinast (pIC50 4.5) [137]
– –
Comments: PDE1A, 1B and 1C appear to act as soluble homod-
imers, while PDE2A is a membrane-bound homodimer. PDE3A
and PDE3B are membrane-bound.
PDE4 isoforms are essentially cyclic AMP specific. The potency
of YM976 at other members of the PDE4 family has not been re-
ported. PDE4B-D long forms are inhibited by extracellular signal-
regulated kinase (ERK)-mediated phosphorylation [212, 213].
PDE4A-D splice variants can be membrane-bound or cytosolic
[217]. PDE4 isoforms may be labelled with [3H]rolipram.
PDE6 is a membrane-bound tetramer composed of two catalytic
chains (PDE6A or PDE6C and PDE6B), an inhibitory chain (PDE6G
or PDE6H) and the PDE6D chain. The enzyme is essentially
cyclic GMP specific and is activated by the α-subunit of transducin
(Gαt) and inhibited by sildenafil, zaprinast and dipyridamole with
potencies lower than those observed for PDE5A. Defects in PDE6B
are a cause of retinitis pigmentosa and congenital stationary night
blindness.
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Cytochrome P450
Enzymes! Cytochrome P450
Overview: The cytochrome P450 enzyme family (CYP450), E.C.
1.14.-.-, were originally defined by their strong absorbance at 450
nm due to the reduced carbon monoxide-complexed haem com-
ponent of the cytochromes. They are an extensive family of
haem-containing monooxygenases with a huge range of both en-
dogenous and exogenous substrates. Listed below are the human
enzymes; their relationship with rodent CYP450 enzyme activi-
ties is obscure in that the species orthologue may not mediate
metabolism of the same substrates. Although the majority of
CYP450 enzyme activities are concentrated in the liver, the extra-
hepatic enzyme activities also contribute to patho/physiological
processes. Genetic variation of CYP450 isoforms is widespread and
likely underlies a significant proportion of the individual variation
to drug administration. Further family members are included on
the online database at www.GuidetoPHARMACOLOGY.org
CYP1 family
Enzymes! Cytochrome P450! CYP1 family
Nomenclature CYP1A1 CYP1A2 CYP1B1
HGNC, UniProt CYP1A1, P04798 CYP1A2, P05177 CYP1B1, Q16678
EC number 1.14.1.1 1.14.1.1 1.14.1.1
Comments – – Mutations have been associated with primary
congenitial glucoma [464]
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CYP2 family
Enzymes! Cytochrome P450! CYP2 family
Nomenclature CYP2A6 CYP2A7 CYP2C8
HGNC, UniProt CYP2A6, P11509 CYP2A7, P20853 CYP2C8, P10632
EC number 1.14.14.1 1.14.14.1 1.14.14.1
Comments Metabolises nicotine CYP2A7 does not incorporate haem and is
functionally inactive [153]
Converts arachidonic acid to 11(R)-12(S)-epoxyeicosatrienoic acid or
14(R)-15(S)-epoxyeicosatrienoic acid [547].
Nomenclature CYP2J2 CYP2R1
HGNC, UniProt CYP2J2, P51589 CYP2R1, Q6VVX0
EC number 1.14.14.1 1.14.13.15
Comments Converts arachidonic acid to
14(R)-15(S)-epoxyeicosatrienoic acid [531].
Converts vitamin D3 to 25-hydroxyvitamin D3 [78].
CYP3 family
Enzymes! Cytochrome P450! CYP3 family
Nomenclature CYP3A4
HGNC, UniProt CYP3A4, P08684
EC number 1.14.13.32: Albendazole + NADPH + O2 = albendazole S-oxide + NADP
+ + H2 1.14.13.157: 1,8-cineole + NADPH + O2 = 2-exo-hydroxy-1,8-cineole +
NADP+ + H2O 1.14.13.97: Taurochenodeoxycholate + NADPH + O2 = taurohyocholate + NADP
+ + H2O
Lithocholate + NADPH + O2 = hyodeoxycholate + NADP
+ + H2O 1.14.13.67: quinine + NADPH + O2 = 3-hydroxyquinine + NADP
+ + H2O2
Substrates atorvastatin [140], codeine [140], diazepam [140], tamoxifen [140], erlotinib [140]
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Nomenclature CYP3A4
Products 4-hydroxy-tamoxifen quinone methide [432], 4-hydroxy-tamoxifen [432]
Comments Metabolises a vast range of xenobiotics, including antidepressants, benzodiazepines, calcium channel blockers, and chemotherapeutic agents. CYP3A4
catalyses the 25-hydroxylation of trihydroxycholestane in liver microsomes [157].
CYP4 family
Enzymes! Cytochrome P450! CYP4 family
Nomenclature CYP4A11 CYP4F2 CYP4F3 CYP4F8 CYP4F12
HGNC,
UniProt
CYP4A11, Q02928 CYP4F2, P78329 CYP4F3, Q08477 CYP4F8, P98187 CYP4F12, Q9HCS2
EC number 1.14.15.3 1.14.13.30 1.14.13.30 1.14.14.1 1.14.14.1
Comments Converts lauric acid to
12-hydroxylauric acid.
Responsible for
!-hydroxylation of LTB4,
LXB4 [335], and
tocopherols, including
vitamin E [453]
Responsible for
!-hydroxylation of LTB4,
LXB4 [335], and
polyunsaturated fatty acids
[135, 194]
Converts PGH2 to
19-hydroxyPGH2 [54] and
8,9-EET or 11,12-EET to
18-hydroxy-8,9-EET or
18-hydroxy-11,12-EET
[353].
AC004597.1
(ENSG00000225607) is
described as being highly
similar to CYP4F12
Nomenclature CYP4F22 CYP4V2 CYP4X1 CYP4Z1
HGNC, UniProt CYP4F22, Q6NT55 CYP4V2, Q6ZWL3 CYP4X1, Q8N118 CYP4Z1, Q86W10
EC number 1.14.14.- 1.14.-.- 1.14.14.1 1.14.14.1
Comments Converts arachidonic acid to
16-HETE and 18-HETE [353].
Converts myristic acid to
14-hydroxymyristic acid [348].
Converts anandamide to
14,15-epoxyeicosatrienoic
ethanolamide [459].
Converts lauric acid to
12-hydroxylauric acid
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CYP5, CYP7 and CYP8 families
Enzymes! Cytochrome P450! CYP5, CYP7 and CYP8 families
Nomenclature CYP5A1 CYP8A1 CYP7A1 CYP7B1 CYP8B1
Common
name
– Prostacyclin synthase – – –
HGNC,
UniProt
TBXAS1, P24557 PTGIS, Q16647 CYP7A1, P22680 CYP7B1, O75881 CYP8B1, Q9UNU6
EC number 5.3.99.5: PGH2 =
thromboxane A2
5.3.99.4 1.14.13.17 1.14.13.100 1.14.13.95
Comments Inhibited by
dazoxiben [398] and
camonagrel [182].
Converts PGH2 to
PGI2 [196]. Inhibited
by tranylcypromine
[181]
Converts cholesterol
to
7α-hydroxycholesterol
[354].
Converts
dehydroepiandrosterone
to 7α-DHEA [411].
Converts 7α-hydroxycholest-4-en-3-one to
7-alpha,12α-dihydroxycholest-4-en-3-one (in
rabbit) [226] in the biosynthesis of bile acids.
CYP11, CYP17, CYP19, CYP20 and CYP21 families
Enzymes! Cytochrome P450! CYP11, CYP17, CYP19, CYP20 and CYP21 families
Nomenclature CYP11A1 CYP11B1 CYP11B2 CYP17A1
Common
name
– – Aldosterone synthase –
HGNC,
UniProt
CYP11A1,
P05108
CYP11B1, P15538 CYP11B2, P19099 CYP17A1, P05093
EC number 1.14.15.6 1.14.15.4 1.14.15.4 1.14.99.9
1.14.15.5
Inhibitors mitotane metyrapone (pIC50 7.8) [553], mitotane osilodrostat (pIC50 9.7) [537] abiraterone (pIC50 7.1–8.4) [386, 390]
Selective
inhibitors
– – – galeterone (pIC50 6.5) [192]
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Nomenclature CYP11A1 CYP11B1 CYP11B2 CYP17A1
Comments Converts
cholesterol to
pregnenolone
plus 4-
methylpentanal.
Converts deoxycortisone and
11-deoxycortisol to cortisone and cortisol,
respectively. Loss-of-function mutations
are associated with familial adrenal
hyperplasia and hypertension. Inhibited
by metyrapone [513]
Converts corticosterone to aldosterone Converts pregnenolone and progesterone
to 17α-hydroxypregnenolone and
17α-hydroxyprogesterone, respectively.
Converts 17α-hydroxypregnenolone and
17α-hydroxyprogesterone to
dehydroepiandrosterone and
androstenedione, respectively. Converts
corticosterone to cortisol.
Nomenclature CYP19A1 CYP20A1 CYP21A2
Common name Aromatase – –
HGNC, UniProt CYP19A1, P11511 CYP20A1, Q6UW02 CYP21A2, P08686
EC number 1.14.14.1 1.14.-.- 1.14.99.10
Inhibitors anastrozole (pIC50 7.8) [343], aminoglutethimide [379] – –
Selective inhibitors letrozole (pKi 10.7) [323], exemestane (pIC50 7.3)
[85], testolactone (pKi 4.5) [95]
– –
Comments Converts androstenedione and testosterone to estrone
and 17β-estradiol, respectively. Inhibited by anastrozole
[388], and letrozole [33]
– Converts progesterone and 17α-hydroxyprogesterone
to deoxycortisone and 11-deoxycortisol, respectively
CYP24, CYP26 and CYP27 families
Enzymes! Cytochrome P450! CYP24, CYP26 and CYP27 families
Nomenclature CYP24A1 CYP26A1 CYP26B1 CYP27A1 CYP27B1
Common abreviation – – – Sterol 27-hydroxylase –
HGNC, UniProt CYP24A1, Q07973 CYP26A1, O43174 CYP26B1, Q9NR63 CYP27A1, Q02318 CYP27B1, O15528
EC number 1.14.13.126 1.14.-.- 1.14.-.- 1.14.13.15 1.14.13.13
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Nomenclature CYP24A1 CYP26A1 CYP26B1 CYP27A1 CYP27B1
Comments Converts
1,25-dihydroxyvitamin D3
(calcitriol) to 1α,24R,25-
trihydroxyvitamin
D3.
Converts retinoic acid to
4-hydroxyretinoic acid.
Inhibited by liarozole
Converts retinoic acid to
4-hydroxyretinoic acid.
Converts cholesterol to
27-hydroxycholesterol.
Converts
25-hydroxyvitamin D3 to
1,25-dihydroxyvitamin D3
(calcitriol)
CYP39, CYP46 and CYP51 families
Enzymes! Cytochrome P450! CYP39, CYP46 and CYP51 families
Nomenclature CYP39A1 CYP46A1 CYP51A1
Common abreviation – Cholesterol 24-hydroxylase Lanosterol 14-α-demethylase
HGNC, UniProt CYP39A1, Q9NYL5 CYP46A1, Q9Y6A2 CYP51A1, Q16850
EC number 1.14.13.99 1.14.13.98 –
Comments Converts 24-hydroxycholesterol to
7α,24-dihydroxycholesterol [286].
Converts cholesterol to
24(S)-hydroxycholesterol.
Converts lanosterol to
4,4-dimethylcholesta-8.14.24-trienol.
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Endocannabinoid turnover
Enzymes! Endocannabinoid turnover
Overview: The principle endocannabinoids are
2-arachidonoylglycerol (2AG) and anandamide (N-
arachidonoylethanolamine, AEA), thought to be generated on
demand rather than stored, although this may not always be
the case [10]. Mechanisms for release and re-uptake of endo-
cannabinoids (and related entities) are unclear, although can-
didates for intracellular transport have been suggested. For
the generation of 2-arachidonoylglycerol, the key enzyme in-
volved is diacylglycerol lipase (DGL), whilst several routes for
anandamide synthesis have been described, the best charac-
terized of which involves N-acylphosphatidylethanolamine-
phospholipase D (NAPE-PLD, [438]). Inactivation of these endo-
cannabinoids appears to occur predominantly through monoa-
cylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH)
for 2-arachidonoylglycerol and anandamide, respectively. Note
that these enzymes also contribute to the turnover of many
endogenous ligands inactive at CB1 and CB2 cannabinoid recep-
tors, such as N-oleoylethanolamide, N-palmitoylethanolamine
and 2-oleoyl glycerol. In vitro experiments indicate that the en-
docannabinoids are also substrates for oxidative metabolism via
cyclooxygenase, lipoxygenase and cytochrome P450 enzyme
activities [9, 145, 450].
Nomenclature Diacylglycerol lipase α Diacylglycerol lipase β N-Acylphosphatidylethanolamine-phospholipase D
Common abreviation DGLα DGLβ NAPE-PLD
HGNC, UniProt DAGLA, Q9Y4D2 DAGLB, Q8NCG7 NAPEPLD, Q6IQ20
EC number 3.1.1.- 3.1.1.- –
Selective inhibitors orlistat (pIC50 7.2) [37], RHC80267
(pIC50 4.2) [243]
orlistat (pIC50 7) [37], RHC80267 –
Comments – – NAPE-PLD activity appears to be enhanced by polyamines in the
physiological range [292], but fails to transphosphatidylate with
alcohols [381] unlike phosphatidylcholine-specific phospholipase D.
Nomenclature Monoacylglycerol lipase Fatty acid amide hydrolase Fatty acid amide hydrolase-2 N-Acylethanolamine acid amidase
Common
abreviation
MGL FAAH FAAH2 NAAA
HGNC, UniProt MGLL, Q99685 FAAH, O00519 FAAH2, Q6GMR7 NAAA, Q02083
EC number 3.1.1.23 3.5.1.- 3.5.1.- 3.5.1.-
Rank order of
affinity
2-oleoyl glycerol =
2-arachidonoylglycerol
anandamide [171]
anandamide > oleamide >
N-oleoylethanolamide >
N-palmitoylethanolamine [518]
oleamide > N-oleoylethanolamide
> anandamide >
N-palmitoylethanolamine [518]
N-palmitoylethanolamine> MEA
> SEA  N-oleoylethanolamide >
anandamide [495]
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Nomenclature Monoacylglycerol lipase Fatty acid amide hydrolase Fatty acid amide hydrolase-2 N-Acylethanolamine acid amidase
Selective
inhibitors
JZL184 (pIC50 8.1) [295] JNJ1661010 (pIC50 7.8) [253],
PF750 (pIC50 6.3–7.8) [4], OL135
(pIC50 7.4) [518], URB597 (pIC50
6.3–7) [518], PF3845 (pIC50 6.6)
[5]
URB597 (pIC50 7.5–8.3) [518],
OL135 (pIC50 7.9) [518]
S-OOPP (pIC50 6.4) [451] – Rat,
CCP (pIC50 5.3) [492]
Comments: Many of the compounds described as inhibitors
are irreversible and so potency estimates will vary with incuba-
tion time. FAAH2 is not found in rodents [518] and few of the
inhibitors described have been assessed at this enzyme activity.
2-arachidonoylglycerol has been reported to be hydrolysed by
multiple enzyme activities from neural preparations, including
ABHD6 (Q9BV23) [41], ABHD12 (8N2K0) [41], neuropathy tar-
get esterase (PNPLA6, Q8IY17 [316]) and carboxylesterase 1 (CES1,
P23141 [533]). Although these have been incompletely defined,
WWL70 has been described to inhibit ABHD6 selectively with a
pIC50 value of 7.2 [284]. Other selective inhibitors of NAAA (with
respect to FAAH) have been described, but these are not yet com-
mercially available.
Further Reading
Blankman JL et al. (2013) Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65:
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and alternative pathways. FEBS J. 280: 1874-94 [PMID:23425575]
Wellner N et al. (2013) N-acylation of phosphatidylethanolamine and its biological functions in
mammals. Biochim. Biophys. Acta 1831: 652-62 [PMID:23000428]
Eicosanoid turnover
Enzymes! Eicosanoid turnover
Overview: Eicosanoids are 20-carbon fatty acids, where the
usual focus is the polyunsaturated analogue arachidonic acid and
its metabolites. Arachidonic acid is thought primarily to de-
rive from phospholipase A2 action on membrane phosphatidyl-
choline, andmay be re-cycled to form phospholipid through con-
jugation with coenzyme A and subsequently glycerol derivatives.
Oxidative metabolism of arachidonic acid is conducted through
three major enzymatic routes: cyclooxygenases; lipoxygenases
and cytochrome P450-like epoxygenases, particularly CYP2J2. Iso-
prostanes are structural analogues of the prostanoids (hence the
nomenclature D-, E-, F-isoprostanes and isothromboxanes), which
are produced in the presence of elevated free radicals in a non-
enzymaticmanner, leading to suggestions for their use as biomark-
ers of oxidative stress. Molecular targets for their action have yet
to be defined.
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Cyclooxygenase
Enzymes! Eicosanoid turnover! Cyclooxygenase
Overview: Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor : oxygen oxidoreductase) activity, catal-
yses the formation of PGG2 from arachidonic acid. Hydroperoxidase activity inherent in the enzyme catalyses the formation of PGH2 from PGG2. COX-1 and -2 can be nonselectively inhibited by
ibuprofen, ketoprofen, naproxen, indomethacin and paracetamol (acetaminophen). PGH2 may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an
apparently tissue-dependent manner.
Nomenclature COX-1 COX-2
HGNC, UniProt PTGS1, P23219 PTGS2, P35354
EC number 1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 =
hydrogen acceptor + H2O + PGH2 arachidonic acid =>
PGG2 => PGH2 This enzyme is also associated with the
following reaction:: docosahexaenoic acid => PGH3
1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 = hydrogen acceptor + H2O + PGH2
arachidonic acid => PGG2 => PGH2 This enzyme is also associated with the following reaction::
docosahexaenoic acid => PGH3
Inhibitors bromfenac (pIC50 8.1) [17], diclofenac (pIC50 7.9)
[556], meclofenamic acid (pIC50 7.3) [247],
flurbiprofen (pIC50 7.1) [512], fenoprofen (pIC50 6.8)
[17], ketoprofen (pIC50 6.5) [55], suprofen (pIC50 6.2)
[55],
benzquinamide (pIC50 8.3) [17], flurbiprofen (pIC50 8) [25], meclofenamic acid (pIC50 7.4) [247],
carprofen (pIC50 7) [209], ketorolac (pIC50 6.9) [503], nimesulide (pIC50 6.2) [366], ketoprofen (pIC50
6.2) [55],
Selective inhibitors ketorolac (pIC50 9.7) [512], FR122047 (pIC50 7.5)
[357]
celecoxib (pIC50 8.7) [38], valdecoxib (pIC50 8.3) [473], diclofenac (pIC50 7.7) [42], rofecoxib (pIC50
6.1–6.5) [512], lumiracoxib (pKi 6.5) [43], meloxicam (pIC50 6.3) [280], etoricoxib (pIC50 6) [406]
Prostaglandin synthases
Enzymes! Eicosanoid turnover! Prostaglandin synthases
Overview: Subsequent to the formation of PGH2, the
cytochrome P450 activities thromboxane synthase (CYP5A1,
TBXAS1, P24557 , EC 5.3.99.5) and prostacyclin synthase
(CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A2
and prostacyclin (PGI2), respectively. Additionally, multiple en-
zyme activities are able to generate prostaglandin E2 (PGE2),
prostaglandin D2 (PGD2) and prostaglandin F2α (PGF2α). PGD2
can be metabolised to 9α,11β-prostacyclin F2α through the multi-
functional enzyme activity of AKR1C3. PGE2 can be metabolised
to 9α,11β-prostaglandin F2α through the 9-ketoreductase activity
of CBR1. Conversion of the 15-hydroxyecosanoids, including
prostaglandins, lipoxins and leukotrienes to their keto derivatives
by the NAD-dependent enzyme HPGD leads to a reduction in
their biological activity.
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Nomenclature CYP5A1 CYP8A1 mPGES1 mPGES2 cPGES
Common
name
– Prostacyclin synthase – – –
HGNC, UniProt TBXAS1, P24557 PTGIS, Q16647 PTGES, O14684 PTGES2, Q9H7Z7 PTGES3, Q15185
EC number 5.3.99.5: PGH2 =
thromboxane A2
5.3.99.4 5.3.99.3: PGH2 =
PGE2
5.3.99.3: PGH2 =
PGE2
5.3.99.3: PGH2 = PGE2
Cofactors – – glutathione dihydrolipoic acid –
Comments Inhibited by
dazoxiben [398] and
camonagrel [182].
Converts PGH2 to
PGI2 [196]. Inhibited
by tranylcypromine
[181]
– – Phosphorylated and activated by casein kinase 2
(CK2) [260].
Appears to regulate steroid hormone function by
interaction with dimeric hsp90 [69, 241].
Nomenclature L-PGDS H-PGDS AKR1C3 CBR1 HPGD
HGNC,
UniProt
PTGDS, P41222 HPGDS, O60760 AKR1C3, P42330 CBR1, P16152 HPGD, P15428
EC number 5.3.99.2: PGH2 = PGD2 5.3.99.2: PGH2 = PGD2 1.3.1.20 1.1.1.188: PGD2
+ NADP+ = PGF2α +
NADPH + H+ 1.1.1.64
1.1.1.239 1.1.1.213
1.1.1.184 1.1.1.189:
PGE2 + NADP
+ = PGF2α
+ NADPH + H+ 1.1.1.197
1.1.1.141
15-hydroxyprostaglandins
=> 15-ketoprostaglandins
LXA4 => 15-keto-lipoxin
A4
Inhibitors – – flufenamic acid,
indomethacin, flavonoids
[321, 446]
– –
Cofactors – – NADP+ NADP+ –
Inhibitors – HQL-79 (pIC50 5.3–5.5)
[15]
– wedelolactone (pIC50 5.4)
[555]
–
Comments – – Also acts as a
hydroxysteroid
dehydrogenase activity.
– –
Comments: YS121 has been reported to inhibit mPGES1 and 5-LOX with a pIC50 value of 5.5 [263].
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Lipoxygenases
Enzymes! Eicosanoid turnover! Lipoxygenases
Overview: The lipoxygenases (LOXs) are a structurally related family of non-heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For
arachidonic acid as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are five lipoxygenases, the 5S-(arachidonate : oxygen 5-oxidoreductase), 12R-(arachidonate
12-lipoxygenase, 12R-type), 12S-(arachidonate : oxygen 12-oxidoreductase), and two distinct 15S-(arachidonate : oxygen 15-oxidoreductase) LOXs that oxygenate arachidonic acid in different positions
along the carbon chain and form the corresponding 5S-, 12S-, 12R-, or 15S-hydroperoxides, respectively.
Nomenclature 5-LOX 12R-LOX 12S-LOX 15-LOX-1 15-LOX-2 E-LOX
HGNC,
UniProt
ALOX5, P09917 ALOX12B,
O75342
ALOX12,
P18054
ALOX15,
P16050
ALOX15B,
O15296
ALOXE3, Q9BYJ1
EC number 1.13.11.34: arachidonic acid +
O2 = LTA4 + H2O
1.13.11.31
arachidonic acid
+ O2 =>
12R-HPETE
1.13.11.31
arachidonic acid
+ O2 =>
12S-HPETE
1.13.11.33:
arachidonic acid
+ O2 =
15S-HPETE
linoleic acid
+ O2 =>
13S-HPODE
1.13.11.33:
arachidonic acid
+ O2 =
15S-HPETE
1.13.11.-
Endogenous
inhibitor
Protein kinase A-mediated
phosphorylation [304]
– – – – –
Substrates –
methyl arachidonate
– – – –
Endogenous
substrates
arachidonic acid – – – – 12R-HPETE
Endogenous
activators
5-LOX activating protein
(ALOX5AP, P20292)
– – – – –
Selective
inhibitors
CJ13610 (pIC50 7.2) [136],
zileuton
– – – – –
Comments FLAP activity can be inhibited by
MK-886 [116] and BAY-X1005
[197] leading to a selective
inhibition of 5-LOX activity
– – – – E-LOX metabolises the product
from the 12R-lipoxygenase
(12R-HPETE) to a specific
epoxyalcohol compound [543].
Comments: An 8-LOX (EC 1.13.11.40, arachidonate:oxygen 8-oxidoreductase) may be the mouse orthologue of 15-LOX-2 [158]. Some general LOX inhibitors are nordihydroguiaretic acid and esculetin.
Zileuton and caffeic acid are used as 5-lipoxygenase inhibitors, while baicalein and CDC are 12-lipoxygenase inhibitors. The specificity of these inhibitors has not been rigorously assessed with all LOX
forms: baicalein, along with other flavonoids, such as fisetin and luteolin, also inhibits 15-LOX-1 [414].
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Leukotriene and lipoxin metabolism
Enzymes! Eicosanoid turnover! Leukotriene and lipoxin metabolism
Overview: Leukotriene A4 (LTA4), produced by 5-LOX activ-
ity, and lipoxins may be subject to further oxidative metabolism;
!-hydroxylation is mediated by CYP4F2 and CYP4F3, while β-
oxidation in mitochondria and peroxisomes proceeds in a man-
ner dependent on coenzyme A conjugation. Conjugation of LTA4
at the 6 position with reduced glutathione to generate LTC4 oc-
curs under the influence of leukotriene C4 synthase, with the
subsequent formation of LTD4 and LTE4, all three of which are
agonists at CysLT receptors. LTD4 formation is catalysed by γ-
glutamyltransferase, and subsequently dipeptidase 2 removes the
terminal glycine from LTD4 to generate LTE4. Leukotriene A4
hydrolase converts the 5,6-epoxide LTA4 to the 5-hydroxylated
LTB4, an agonist for BLT receptors. LTA4 is also acted upon by
12S-LOX to produce the trihydroxyeicosatetraenoic acids lipox-
ins LXA4 and LXB4. Treatment with a LTA4 hydrolase inhibitor
in amurinemodel of allergic airway inflammation increased LXA4
levels, in addition to reducing LTB4, in lung lavage fluid [400].
LTA4 hydrolase is also involved in biosynthesis of resolvin Es.
Aspirin has been reported to increase endogenous forma-
tion of 18S-hydroxyeicosapentaenoate (18S-HEPE) compared
with 18R-HEPE, a resolvin precursor. Both enantiomers may
be metabolised by human recombinant 5-LOX; recombinant
LTA4 hydrolase converted chiral 5S(6)-epoxide-containing inter-
mediates to resolvin E1 and 18S-resolvin E1 [358].
Nomenclature Leukotriene C4 synthase γ-Glutamyltransferase Dipeptidase 1 Dipeptidase 2
HGNC, UniProt LTC4S, Q16873 GGCT, O75223 DPEP1, P16444 DPEP2, Q9H4A9
EC number 4.4.1.20: LTC4 = glutathione +
LTA4
2.3.2.2: (5-L-glutamyl)-peptide +
an amino acid = a peptide + a
5-L-glutamyl amino acid LTC4 +
H2O => LTD4 + L-glutamate
3.4.13.19: LTD4 + H2O = LTE4 +
glycine
3.4.13.19: LTD4 + H2O = LTE4 +
glycine
Inhibitors – – cilastatin (pKi 6) [179] – Unknown –
Comments: LTA4H is a member of a family of arginyl aminopep-
tidases (ENSFM00250000001675), which also includes aminopep-
tidase B (RNPEP, 9H4A4) and aminopeptidase B-like 1 (RNPEPL1,
Q9HAU8). Dipeptidase 1 and 2 are members of a family of mem-
brane dipeptidases, which also includes (DPEP3, Q9H4B8) for
which LTD4 appears not to be a substrate.
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GABA turnover
Enzymes! GABA turnover
Overview: The inhibitory neurotransmitter γ-aminobutyrate
(GABA, 4-aminobutyrate) is generated in neurones by glutamic
acid decarboxylase. GAD1 and GAD2 are differentially expressed
during development, where GAD2 is thought to subserve a trophic
role in early life and is distributed throughout the cytoplasm.
GAD1 is expressed in later life and is more associated with nerve
terminals [128] where GABA is principally accumulated in vesi-
cles through the action of the vesicular inhibitory amino acid
transporter SLC32A1. The role of γ-aminobutyraldehyde de-
hydrogenase (ALDH9A1) in neurotransmitter GABA synthesis is
less clear. Following release from neurons, GABA may interact
with either GABAA or GABAB receptors and may be accumu-
lated in neurones and glia through the action of members of
the SLC6 family of transporters. Successive metabolism through
GABA transaminase and succinate semialdehyde dehydrogenase
generates succinic acid, which may be further metabolized in the
mitochondria in the tricarboxylic acid cycle.
Nomenclature Glutamic acid aldehyde dehydrogenase 9 4-aminobutyrate aldehyde dehydrogenase 5
decarboxylase 1, family, member A1 aminotransferase family, member A1
decarboxylase 2
Common abreviation GAD1, GAD2 – GABA-T SSADH
HGNC, UniProt GAD1, Q99259, ALDH9A1, P49189 ABAT, P80404 ALDH5A1, P51649
GAD2, Q05329
EC number 4.1.1.15: L-glutamic acid + H+ ->
GABA + CO2
1.2.1.19: 4-aminobutanal + NAD
+ H2O = GABA + NADH + H
+
1.2.1.47:
4-trimethylammoniobutanal +
NAD + H2O =
4-trimethylammoniobutanoate +
NADPH + 2H+ 1.2.1.3: an
aldehyde + H2O + NAD = a
carboxylate + 2H+ + NADH
2.6.1.19: GABA +
α-ketoglutaric acid =
L-glutamic acid + 4-oxobutanoate
2.6.1.22:
(S)-3-amino-2-methylpropanoate
+ α-ketoglutaric acid =
2-methyl-3-oxopropanoate +
L-glutamic acid
1.2.1.24: 4-oxobutanoate + NAD
+ H2O = succinic acid + NADH +
2H+
4-hydroxy-trans-2-nonenal + NAD
+ H2O =
4-hydroxy-trans-2-nonenoate +
NADH + 2H+
Endogenous
substrates
L-glutamic acid, L-aspartic acid – – –
Products GABA – – –
Cofactors pyridoxal phosphate NAD pyridoxal phosphate NAD [432]
Inhibitors – – vigabatrin (Irreversible inhibition)
(pKi 3.1) [289, 437]
–
Selective inhibitors s-allylglycine – – –
Comments L-aspartic acid is a less rapidly
metabolised substrate of mouse
brain glutamic acid decarboxylase
generating β-alanine [530].
Autoantibodies against GAD1 and
GAD2 are elevated in type 1
diabetes mellitus and neurological
disorders (see Further reading).
– – –
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Glycerophospholipid turnover
Enzymes! Glycerophospholipid turnover
Overview: Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine,
phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).
Phosphatidylinositol kinases
Enzymes! Glycerophospholipid turnover! Phosphatidylinositol kinases
Overview:
Phosphatidylinositol may be phosphorylated at either 3- or 4- po-
sitions on the inositol ring by PI 3-kinases or PI 4-kinases, respec-
tively.
Phosphatidylinositol 3-kinases
Phosphatidylinositol 3-kinases (PI3K, provisional nomenclature)
catalyse the introduction of a phosphate into the 3-position
of phosphatidylinositol (PI), phosphatidylinositol 4-phosphate
(PIP) or phosphatidylinositol 4,5-bisphosphate (PIP2). There
is evidence that PI3K can also phosphorylate serine/threonine
residues on proteins. In addition to the classes described be-
low, further serine/threonine protein kinases, including ATM
(Q13315) and mTOR (P42345), have been described to phos-
phorylate phosphatidylinositol and have been termed PI3K-
related kinases. Structurally, PI3K have common motifs of at
least one C2, calcium-binding domain and helical domains,
alongside structurally-conserved catalytic domains. Wortmannin
and LY294002 are widely-used inhibitors of PI3K activities.
Wortmannin is irreversible and shows modest selectivity between
Class I and Class II PI3K, while LY294002 is reversible and selective
for Class I compared to Class II PI3K.
Class I PI3Ks (EC 2.7.1.153) phosphorylate phosphatidyli-
nositol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-
trisphosphate and are heterodimeric, matching catalytic and reg-
ulatory subunits. Class IA PI3Ks include p110α, p110β and p110Æ
catalytic subunits, with predominantly p85 and p55 regulatory
subunits. The single catalytic subunit that forms Class IB PI3K is
p110γ. Class IA PI3Ks are more associated with receptor tyrosine
kinase pathways, while the Class IB PI3K is linkedmorewith GPCR
signalling.
Class II PI3Ks (EC 2.7.1.154) phosphorylate phosphatidylinos-
itol to generate phosphatidylinositol 3-phosphate (and possibly
phosphatidylinositol 4-phosphate to generate phosphatidylinos-
itol 3,4-bisphosphate). Three monomeric members exist, PI3K-
C2α, β and γ, and include Ras-binding, Phox homology and two
C2domains.
The only class III PI3K isoform (EC 2.7.1.137) is a heterodimer
formed of a catalytic subunit (VPS34) and regulatory subunit
(VPS15).
Phosphatidylinositol 4-kinases
Phosphatidylinositol 4-kinases (EC 2.7.1.67) generate phos-
phatidylinositol 4-phosphate and may be divided into higher
molecular weight type III and lower molecular weight type II
forms.
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1-phosphatidylinositol 4-kinase family
Enzymes! Kinases (EC 2.7.x.x)! Lipid modifying kinases! 1-phosphatidylinositol 4-kinase family
Nomenclature phosphatidylinositol 4-kinase, catalytic, alpha phosphatidylinositol 4-kinase, catalytic, beta
Common abreviation PI4KIIIα/PIK4CA PI4KIIIβ/PIK4CB
HGNC, UniProt PI4KA, P42356 PI4KB, Q9UBF8
EC number 2.7.1.67 2.7.1.67
Endogenous activation – PKD-mediated phosphorylation [199]
(Sub)family-selective inhibitors wortmannin (pIC50 6.7–6.8) [170, 329] wortmannin (pIC50 6.7–6.8) [170, 329]
Selective inhibitors – PIK-93 [259]
Phosphatidylinositol-4-phosphate 3-kinase family
Enzymes! Kinases (EC 2.7.x.x)! Lipid modifying kinases! Phosphatidylinositol-4-phosphate 3-kinase family
Nomenclature phosphatidylinositol-4-phosphate 3-kinase, phosphatidylinositol-4-phosphate 3-kinase, phosphatidylinositol-4-phosphate 3-kinase,
catalytic subunit type 2 alpha catalytic subunit type 2 beta catalytic subunit type 2 gamma
Common abreviation C2α/PIK3C2A C2β/PIK3C2B C2γ/PIK3C2G
HGNC, UniProt PIK3C2A, O00443 PIK3C2B, O00750 PIK3C2G, O75747
EC number 2.7.1.154 2.7.1.154 2.7.1.154
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Phosphatidylinositol 3-kinase family
Enzymes! Kinases (EC 2.7.x.x)! Lipid modifying kinases! Phosphatidylinositol 3-kinase family
Nomenclature phosphatidylinositol 3-kinase, catalytic subunit type 3
Common abreviation VPS34/PIK3C3
HGNC, UniProt PIK3C3, Q8NEB9
EC number 2.7.1.137
Phosphatidylinositol-4,5-bisphosphate 3-kinase family
Enzymes! Kinases (EC 2.7.x.x)! Lipid modifying kinases! Phosphatidylinositol-4,5-bisphosphate 3-kinase family
Nomenclature phosphatidylinositol-4, phosphatidylinositol-4, phosphatidylinositol-4, phosphatidylinositol-4,
5-bisphosphate 3-kinase, 5-bisphosphate 3-kinase, 5-bisphosphate 3-kinase, 5-bisphosphate 3-kinase,
catalytic subunit alpha catalytic subunit beta catalytic subunit gamma catalytic subunit delta
Common
abreviation
p110α/PIK3CA p110β/PIK3CB p110γ/PIK3CG p110Æ/PIK3CD
HGNC, UniProt PIK3CA, P42336 PIK3CB, P42338 PIK3CG, P48736 PIK3CD, O00329
EC number 2.7.1.153 2.7.1.153 2.7.1.153 2.7.1.153
2.7.11.1
Inhibitors PIK-75 (pIC50 9.5) [200],
gedatolisib (pIC50 9.4) [500],
PF-04691502 (pKi 9.2) [290],
PI-103 (pIC50 8.7) [404], BGT-226
(pIC50 8.4) [315], KU-0060648
(pIC50 8.4) [60], dactolisib (pIC50
8.4) [310], apitolisib (pIC50 8.3)
[467], alpelisib (pIC50 8.3) [155],
PIK-75 (pIC50 8.2) [259], buparlisib
(pIC50 7.5) [49], PP121 (pIC50 7.3)
[14]
KU-0060648 (pIC50 9.3) [60],
PI-103 (pIC50 8.5) [404], AZD6482
(pIC50 8) [355], ZSTK474 (pIC50
7.8) [535], apitolisib (pIC50 7.6)
[467], BGT-226 (pIC50 7.2) [315]
dactolisib (pIC50 8.3) [310],
apitolisib (pIC50 7.8) [467], PI-103
(pIC50 7.8) [404], BGT-226 (pIC50
7.4) [315], ZSTK474 (pIC50 7.3)
[535], TG-100-115 (pIC50 7.1)
[369], alpelisib (pIC50 6.6) [155],
KU-0060648 (pIC50 6.2) [60]
KU-0060648 (pIC50 >10) [60],
idelalisib (in vitro activity against
recombinant enzyme) (pIC50 8.6)
[276], PI-103 (pIC50 8.5) [404],
ZSTK474 (pIC50 8.2) [535],
apitolisib (pIC50 8.2) [467],
dactolisib (pIC50 8.1) [310],
alpelisib (pIC50 6.5) [155]
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(continued)
Nomenclature phosphatidylinositol-4, phosphatidylinositol-4, phosphatidylinositol-4, phosphatidylinositol-4,
5-bisphosphate 3-kinase, 5-bisphosphate 3-kinase, 5-bisphosphate 3-kinase, 5-bisphosphate 3-kinase,
catalytic subunit alpha catalytic subunit beta catalytic subunit gamma catalytic subunit delta
(Sub)family-
selective
inhibitors
pictilisib (pIC50 8.5) [141] pictilisib (pIC50 7.5) [141] pictilisib (pIC50 7.1) [141] pictilisib (pIC50 8.5) [141]
Selective
inhibitors
– – CZC 24832 (pKd 7.7) [30],
CZC 24832 (pIC50 7.6) [30]
–
1-phosphatidylinositol-3-phosphate 5-kinase family
Enzymes! Kinases (EC 2.7.x.x)! Lipid modifying kinases! 1-phosphatidylinositol-3-phosphate 5-kinase family
Nomenclature phosphoinositide kinase, FYVE finger containing
HGNC, UniProt PIKFYVE, Q9Y2I7-4
EC number 2.7.1.150: ATP + 1-phosphatidyl-1D-myo-inositol 3-phosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate
Type I PIP kinases (1-phosphatidylinositol-4-phosphate 5-kinase family)
Enzymes! Kinases (EC 2.7.x.x)! Lipid modifying kinases! Type I PIP kinases (1-phosphatidylinositol-4-phosphate 5-kinase family)
Overview: Type I PIP kinases are required for the production of the second messenger phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(4)P [397]. This enzyme family is
also known as type I PIP(5)Ks.
Nomenclature phosphatidylinositol-4-phosphate 5-kinase, type I, alpha phosphatidylinositol-4-phosphate 5-kinase, type I, gamma
Common abreviation PIP5K1A PIP5K1C
HGNC, UniProt PIP5K1A, Q99755 PIP5K1C, O60331
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(continued)
Nomenclature phosphatidylinositol-4-phosphate 5-kinase, type I, alpha phosphatidylinositol-4-phosphate 5-kinase, type I, gamma
EC number 2.7.1.68 2.7.1.68
Inhibitors ISA-2011B [428] –
Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-kinase family)
Enzymes! Kinases (EC 2.7.x.x)! Lipid modifying kinases! Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-kinase family)
Overview: Type II PIP kinases are essential for the production of the second messenger phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(5)P [397]. This enzyme family
is also known as type II PIP(5)Ks.
Nomenclature phosphatidylinositol-5-phosphate 4-kinase, phosphatidylinositol-5-phosphate 4-kinase,
phosphatidylinositol-5-phosphate 4-kinase,
type II, alpha type II, beta type II, gamma
Common abreviation – PIP4K2B PIP4K2C
HGNC, UniProt PIP4K2A, P48426 PIP4K2B, P78356 PIP4K2C, Q8TBX8
EC number 2.7.1.149 2.7.1.149 2.7.1.149
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate <=>
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
Further Reading
Neubauer HA et al. (2013) Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J. 280:
5317-36 [PMID:23638983]
Truman JP et al. (2014) Evolving concepts in cancer therapy through targeting sphingolipid
metabolism. Biochim. Biophys. Acta 1841: 1174-88 [PMID:24384461]
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Phosphoinositide-specific phospholipase C
Enzymes! Glycerophospholipid turnover! Phosphoinositide-specific phospholipase C
Overview: Phosphoinositide-specific phospholipase C (PLC,
EC 3.1.4.11), catalyses the hydrolysis of PIP2 to IP3 and 1,2-
diacylglycerol, each of which have major second messenger func-
tions. Two domains, X and Y, essential for catalytic activity,
are conserved in the different forms of PLC. Isoforms of PLC-β
are activated primarily by G protein-coupled receptors through
members of the Gq/11 family of G proteins. The receptor-
mediated activation of PLC-γ involves their phosphorylation by
receptor tyrosine kinases (RTK) in response to activation of a vari-
ety of growth factor receptors and immune system receptors. PLC-
1 may represent a point of convergence of signalling via both G
protein-coupled and catalytic receptors. Ca2+ ions are required for
catalytic activity of PLC isoforms and have been suggested to be
the major physiological form of regulation of PLC-Æ activity. PLC
has been suggested to be activated non-selectively by the small
molecule m3M3FBS [21], although this mechanism of action has
been questioned [271]. The aminosteroid U73122 has been de-
scribed as an inhibitor of phosphoinositide-specific PLC [447], al-
though its selectivity among the isoforms is untested and it has
been reported to occupy the H1 histamine receptor [222].
Nomenclature PLCβ1 PLCβ2 PLCβ3 PLCβ4 PLCγ1 PLCγ2
HGNC, UniProt PLCB1, Q9NQ66 PLCB2, Q00722 PLCB3,
Q01970
PLCB4,
Q15147
PLCG1,
P19174
PLCG2, P16885
Endogenous
activators
Gαq, Gα11, Gβγ
[207, 374, 449]
Gα16, Gβγ, Rac2
(RAC2, P15153) [59,
223, 224, 281, 374]
Gαq, Gβγ [65,
281, 374]
Gαq [237] PIP3 [20] PIP3, Rac1 (RAC1, P63000), Rac2
(RAC2, P15153), Rac3 (RAC3,
P60763) [20, 384, 507]
Nomenclature PLCÆ1 PLCÆ3 PLCÆ4 PLC1 PLC1 PLC1 PLC2
HGNC, UniProt PLCD1, P51178 PLCD3,
Q8N3E9
PLCD4,
Q9BRC7
PLCE1,
Q9P212
PLCZ1, Q86YW0 PLCH1, Q4KWH8 PLCH2,
O75038
Endogenous
activators
Transglutaminase II,
p122-RhoGAP {Rat},
spermine, Gβγ [187, 214,
344, 374]
– – Ras, rho
[452, 525]
– – Gβγ [551]
Endogenous
inhibitors
Sphingomyelin [378] – – – – – –
Comments: A series of PLC-like proteins (PLCL1, Q15111; PLCL2, Q9UPR0 and PLCH1, Q4KWH8) form a family with PLCÆ and PLC1 isoforms, but appear to lack catalytic activity.
PLC-Æ2 has been cloned from bovine sources [328].
Searchable database: http://www.guidetopharmacology.org/index.jsp Phosphoinositide-specific phospholipase C 6087
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13354/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. British Journal of Pharmacology (2015) 172, 6024–6109
Phospholipase A2
Enzymes! Glycerophospholipid turnover! Phospholipase A2
Overview: Phospholipase A2 (PLA2, EC 3.1.1.4) cleaves
the sn-2 fatty acid of phospholipids, primarily phos-
phatidylcholine, to generate lysophosphatidylcholine and
arachidonic acid. Most commonly-used inhibitors (e.g.
bromoenol lactone, arachidonyl trifluoromethyl ketone or
methyl arachidonyl fluorophosphonate) are either non-selective
within the family of phospholipase A2 enzymes or have activity
against other eicosanoid-metabolising enzymes.
Secreted or extracellular forms: sPLA2-1B, sPLA2-2A, sPLA2-
2D, sPLA2-2E, sPLA2-2F, sPLA2-3, sPLA2-10 and sPLA2-12A
Cytosolic, calcium-dependent forms: cPLA2-4A, cPLA2-4B,
cPLA2-4C, cPLA2-4D, cPLA2-4E and cPLA2-4F
Other forms: PLA2-G5, iPLA2-G6, PLA2-G7 and PAFAH2
(platelet-activating factor acetylhydrolase 2)
Nomenclature sPLA2-1B sPLA2-2A sPLA2-2D sPLA2-2E sPLA2-2F
HGNC, UniProt PLA2G1B, P04054 PLA2G2A, P14555 PLA2G2D, Q9UNK4 PLA2G2E, Q9NZK7 PLA2G2F, Q9BZM2
Nomenclature sPLA2-3 sPLA2-10 sPLA2-12A cPLA2-4A cPLA2-4B
HGNC, UniProt PLA2G3, Q9NZ20 PLA2G10, O15496 PLA2G12A, Q9BZM1 PLA2G4A, P47712 PLA2G4B, P0C869
Comments – – – cPLA2-4A also expresses
lysophospholipase
(EC 3.1.1.5) activity [435].
–
Nomenclature cPLA2-4C cPLA2-4D cPLA2-4E cPLA2-4F
HGNC, UniProt PLA2G4C, Q9UP65 PLA2G4D, Q86XP0 PLA2G4E, Q3MJ16 PLA2G4F, Q68DD2
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Nomenclature PLA2-G5 iPLA2-G6 PLA2-G7 platelet-activating factor
acetylhydrolase 2, 40kDa
HGNC, UniProt PLA2G5, P39877 PLA2G6, O60733 PLA2G7, Q13093 PAFAH2, Q99487
Inhibitors – – darapladib (pIC50 10) [39] –
Selective inhibitors – – rilapladib (Competitive) (pIC50 9.6) [523] –
Comments – – – PAFAH2 also expresses PAF hydrolase
activity (EC 3.1.1.47)
Comments: The sequence of PLA2-2C suggests a lack of catalytic
activity, while PLA2-12B (GXIIB, GXIII sPLA2-like) appears to be
catalytically inactive [413]. A further fragment has been identified
with sequence similarities to Group II PLA2 members. Otoconin
90 (OC90) shows sequence homology to PLA2-G10.
A binding protein for secretory phospholipase A2 has been identi-
fied which shows modest selectivity for sPLA2-1B over sPLA2-2A,
and also binds snake toxin phospholipase A2 [12]. The binding
protein appears to have clearance function for circulating secre-
tory phospholipase A2, as well as signalling functions, and is a
candidate antigen for idiopathic membraneous nephropathy [27].
PLA2-G7 and PAFAH2 also express platelet-activating factor
acetylhydrolase activity (EC 3.1.1.47).
Phosphatidylcholine-specific phospholipase D
Enzymes! Glycerophospholipid turnover! Phosphatidylcholine-specific phospholipase D
Overview: Phosphatidylcholine-specific phospholipase D (PLD, EC 3.1.1.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols,
such as butanol in a transphosphatidylation reaction [399].
Nomenclature PLD1 PLD2
HGNC, UniProt PLD1, Q13393 PLD2, O14939
Endogenous activators ADP-ribosylation factor 1 (ARF1, P84077), PIP2, RhoA, PKC evoked
phosphorylation, RalA [189, 303]
–
Endogenous inhibitor Gβγ [391] Gβγ [391]
Endogenous activators – ADP-ribosylation factor 1 (ARF1, P84077), PIP2 [298], oleic acid [418]
Selective inhibitors – VU0364739 (pIC50 7.7) [279]
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Comments: A lysophospholipase D activity (ENPP2,
Q13822, also known as ectonucleotide pyrophos-
phatase/phosphodiesterase 2, phosphodiesterase I, nucleotide
pyrophosphatase 2, autotaxin) has been described, which not
only catalyses the production of lysophosphatidic acid (LPA)
from lysophosphatidylcholine, but also cleaves ATP (see God-
ing et al., 2003 [175]). Additionally, an N-acylethanolamine-
specific phospholipase D (NAPEPLD, Q6IQ20) has been char-
acterized, which appears to have a role in the generation of
endocannabinoids/endovanilloids, including anandamide [362].
This enzyme activity appears to be enhanced by polyamines in
the physiological range [292] and fails to transphosphatidylate
with alcohols [381].
Three further, less well-characterised isoforms are PLD3 (PLD3,
Q8IV08, other names Choline phosphatase 3, HindIII K4L ho-
molog, Hu-K4), PLD4 (PLD4, Q96BZ4, other names Choline
phosphatase 4, Phosphatidylcholine-hydrolyzing phospholipase,
D4C14orf175 UNQ2488/PRO5775) and PLD5 (PLD5, Q8N7P1).
PLD3 has been reported to be involved in myogenesis [365]. PLD4
is described not to have phospholipase D catalytic activity [539],
but has been associated with inflammatory disorders [360, 468,
484]. Sequence analysis suggests that PLD5 is catalytically inac-
tive.
Lipid phosphate phosphatases
Enzymes! Glycerophospholipid turnover! Lipid phosphate phosphatases
Overview: Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to
generate inorganic phosphate and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase which acts
as a tumour suppressor by reducing cellular levels of PI 3,4,5-P, thereby toning down activity of PDK1 and PKB. Loss-of-function mutations are frequently identified as somatic mutations in cancers.
Nomenclature Lipin1 Lipin2 Lipin3 PPA2A PPA2B PPA3A phosphatase and
tensin homolog
HGNC,
UniProt
LPIN1,
Q14693
LPIN2, Q92539 LPIN3,
Q9BQK8
PPAP2A,
O14494
PPAP2B, O14495 PPAP2C,
O43688
PTEN, P60484
EC number 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.67
3.1.3.48
3.1.3.16
Substrates – phosphatidic acid – – phosphatidic acid – phosphatidylinositol
(3,4,5)-trisphosphate
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Haem oxygenase
Enzymes! Haem oxygenase
Overview: Haem oxygenase (heme,hydrogen-donor:oxygen oxidoreductase (α-methene-oxidizing, hydroxylating)), E.C. 1.14.99.3, converts heme into biliverdin and carbonmonoxide, utilizing NADPH
as cofactor.
Nomenclature Haem oxygenase 1 Haem oxygenase 2
Common abreviation HO1 HO2
HGNC, UniProt HMOX1, P09601 HMOX2, P30519
EC number 1.14.99.3 1.14.99.3
Comments: The existence of a third non-catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene [202]. The chemical tin protoporphyrin IX
acts as a haem oxygenase inhibitor in rat liver with an IC50 value of 11 nM [120].
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Hydrogen sulphide synthesis
Enzymes! Hydrogen sulphide synthesis
Overview: Hydrogen sulfide is a putative gasotransmitter, with similarities to nitric oxide and carbon monoxide. Although the enzymes indicated have multiple enzymatic activities, the focus here is
the generation of hydrogen sulphide and the enzymatic characteristics are described accordingly. Cystathionine β-synthase and cystathionine γ-lyase are pyridoxal phosphate-dependent enzymes, while
3-mercaptopyruvate sulfurtransferase functions as a pyridoxal phosphate-independent pathway.
Nomenclature Cystathionine β-synthase Cystathionine γ-lyase L-Cysteine:2-oxoglutarate 3-Mercaptopyruvate
aminotransferase sulfurtransferase
Common
abreviation
CBS CSE CAT MPST
HGNC, UniProt CBS, P35520 CTH, P32929 CCBL1, Q16773 MPST, P25325
EC number 4.2.1.22 4.4.1.1 4.4.1.13 2.8.1.2
Endogenous
substrates
L-cysteine (Km 610 3M) [74],
L-homocysteine
L-cysteine L-cysteine 3-mercaptopyruvic acid (Km
1.210 3M) [345]
Products cystathionine NH3, pyruvic acid NH3, pyruvic acid pyruvic acid
Cofactors pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate Zn2+
Inhibitors aminooxyacetic acid propargylglycine – –
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Hydrolases
Enzymes! Hydrolases
Overview: Listed in this section are hydrolases not accumulated in other parts of the Concise Guide, such as monoacylglycerol lipase and acetylcholinesterase. Pancreatic lipase is the predominant
mechanism of fat digestion in the alimentary system; its inhibition is associated with decreased fat absorption. CES1 is present at lower levels in the gut than CES2 (P23141), but predominates in the
liver, where it is responsible for the hydrolysis of many aliphatic, aromatic and steroid esters. Hormone-sensitive lipase is also a relatively non-selective esterase associated with steroid ester hydrolysis and
triglyceride metabolism, particularly in adipose tissue. Endothelial lipase is secreted from endothelial cells and regulates circulating cholesterol in high density lipoproteins.
Nomenclature pancreatic lipase lipase, endothelial carboxylesterase 1 lipase, hormone-sensitive
Common abreviation PNLIP LIPG CES1 LIPE
HGNC, UniProt PNLIP, P16233 LIPG, Q9Y5X9 CES1, P23141 LIPE, Q05469
EC number 3.1.1.3 3.1.1.3 3.1.1.1 3.1.1.79
Inhibitors orlistat (pIC50 8.9) [51] – – –
Further Reading
Markey, G.M. (2011) Carboxylesterase 1 (Ces1): from monocyte marker to major player. J Clin Pathol 64: 107-109 [PMID:21177752]
Inositol phosphate turnover
Enzymes! Inositol phosphate turnover
Overview: The sugar alcohol D-myo-inositol is a component of
the phosphatidylinositol signalling cycle, where the principal sec-
ond messenger is inositol 1,4,5-trisphosphate, IP3, which acts at
intracellular ligand-gated ion channels, IP3 receptors to elevate
intracellular calcium. IP3 is recycled to inositol by phosphatases
or phosphorylated to form other active inositol polyphosphates.
Inositol produced from dephosphorylation of IP3 is recycled
into membrane phospholipid under the influence of phos-
phatidyinositol synthase activity (CDP-diacylglycerol-inositol 3-
phosphatidyltransferase [EC 2.7.8.11]).
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Inositol 1,4,5-trisphosphate 3-kinases
Enzymes! Inositol phosphate turnover! Inositol 1,4,5-trisphosphate 3-kinases
Overview: Inositol 1,4,5-trisphosphate 3-kinases (E.C. 2.7.1.127, ENSFM00250000001260) catalyse the generation of inositol 1,3,4,5-tetrakisphosphate (IP4) from IP3. IP3 kinase activity is enhanced in
the presence of calcium/calmodulin (CALM1 CALM2 CALM3, P62158) [91].
Inositol polyphosphate phosphatases
Enzymes! Inositol phosphate turnover! Inositol polyphosphate phosphatases
Overview: Members of this family exhibit phosphatase activity towards IP3, as well as towards other inositol derivatives, including the phospholipids PIP2 and PIP3. With IP3 as substrate, 1-phosphatase
(EC 3.1.3.57) generates 4,5,-IP2, 4-phosphatases (EC 3.1.3.66, ENSFM00250000001432) generate 1,5,-IP2 and 5-phosphatases (E.C. 3.1.3.36 or 3.1.3.56) generate 1,4,-IP2.
Comments: In vitro analysis suggested IP3 and IP4 were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that PIP2 and PIP3 were more efficiently hydrolysed [422].
Inositol monophosphatase
Enzymes! Inositol phosphate turnover! Inositol monophosphatase
Overview: Inositol monophosphatase (E.C. 3.1.3.25, IM-
Pase, myo-inositol-1(or 4)-phosphate phosphohydrolase) is a
magnesium-dependent homodimer which hydrolyses myo-
inositol monophosphate to generate myo-inositol and phosphate.
Glycerol may be a physiological phosphate acceptor. Li+ is a
nonselective un-competitive inhibitor more potent at IMPase 1
(pKi ca. 3.5, [324]; pIC50 3.2, [359]) than IMPase 2 (pIC50 1.8-
2.1, [359]). IMPase activity may be inhibited competitively by
L690330 (pKi 5.5, [324]), although the enzyme selectivity is not
yet established.
Nomenclature IMPase 1 IMPase 2
HGNC, UniProt IMPA1, P29218 IMPA2, O14732
EC number 3.1.3.25 3.1.3.25
Rank order of affinity inositol 4-phosphate > inositol 3-phosphate > inositol 1-phosphate [324] –
Inhibitors Li+ (pKi 3.5) [324] –
Comments: Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder [443, 444, 540]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears
to mimic the effects of Li+ in mice [97, 98].
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Lanosterol biosynthesis pathway
Enzymes! Lanosterol biosynthesis pathway
Overview: Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG-CoA reductase pathway. The first two steps
(formation of acetoacetyl CoA and the mitochondrial generation of (S)-3-hydroxy-3-methylglutaryl-CoA) are also associated with oxidation of fatty acids.
Nomenclature acetyl-CoA acetyltransferase 1, acetyl-CoA acetyltransferase 2 hydroxymethylglutaryl-CoA synthase 1, hydroxymethylglutaryl-CoA synthase 2
HGNC, UniProt ACAT1, P24752, ACAT2, Q9BWD1 HMGCS1, Q01581, HMGCS2, P54868
EC number 2.3.1.9: 2acetyl CoA = acetoacetyl CoA + coenzyme A 2.3.3.10: acetyl CoA + H2O + acetoacetyl CoA ->
(S)-3-hydroxy-3-methylglutaryl-CoA + coenzyme A
Comments – HMGCoA synthase is found in cytosolic (HMGCoA synthase 1) and mitochondrial
(HMGCoA synthase 2) versions; the former associated with (R)-mevalonate
synthesis and the latter with ketogenesis.
Nomenclature hydroxymethylglutaryl-CoA mevalonate kinase phosphomevalonate kinase diphosphomevalonate
reductase decarboxylase
HGNC, UniProt HMGCR, P04035 MVK, Q03426 PMVK, Q15126 MVD, P53602
EC number 1.1.1.34: (S)-3-hydroxy-3-methylglutaryl-CoA
+ NADPH -> (R)-mevalonate + coenzyme A +
NADP+ Reaction mechanism:: First step:
(S)-3-hydroxy-3-methylglutaryl-CoA + NADPH
-> mevaldyl-CoA + NADP+
Second step: mevaldyl-CoA + H2O ->
(R)-mevalonate + NADP+
2.7.1.36: ATP +
(R)-mevalonate ->
adenosine diphosphate +
(R)-5-phosphomevalonate
2.7.4.2: ATP +
(R)-5-phosphomevalonate =
adenosine diphosphate +
(R)-5-diphosphomevalonate
4.1.1.33: ATP +
(R)-5-diphosphomevalonate ->
adenosine diphosphate +
isopentenyl diphosphate + CO2 +
PO3
4-
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(continued)
Nomenclature hydroxymethylglutaryl-CoA mevalonate kinase phosphomevalonate kinase diphosphomevalonate
reductase decarboxylase
Inhibitors lovastatin (Competitive) (pKi 9.2) [8],
rosuvastatin (Competitive) (pIC50 8.3) [228],
cerivastatin (Competitive) (pKi 8.2) [61],
atorvastatin (Competitive) (pIC50 8.1) [228],
cerivastatin (Competitive) (pIC50 8) [486],
simvastatin (Competitive) (pIC50 8) [228],
fluvastatin (Competitive) (pIC50 7.6) [228]
– – –
Comments HMGCoA reductase is associated with
intracellular membranes; enzymatic activity is
inhibited by phosphorylation by AMP-activated
kinase. The enzymatic reaction is a three-step
reaction involving the intermediate generation
of mevaldehyde-CoA and mevaldehyde.
Mevalonate kinase activity is
regulated by the downstream
products
farnesyl diphosphate and
geranyl diphosphate as an
example of feedback
inhibition.
– –
Nomenclature isopentenyl-diphosphate isopentenyl-diphosphate geranylgeranyl diphosphate synthase farnesyl diphosphate synthase
1-isomerase 1 1-isomerase 1
HGNC, UniProt IDI1, Q13907 IDI2, Q9BXS1 GGPS1, O95749 FDPS, P14324
EC number 5.3.3.2: isopentenyl diphosphate
= dimethylallyl diphosphate
5.3.3.2: isopentenyl diphosphate
= dimethylallyl diphosphate
2.5.1.29:
trans,trans-farnesyl diphosphate +
isopentenyl diphosphate ->
geranylgeranyl diphosphate +
diphosphate 2.5.1.10:
geranyl diphosphate +
isopentenyl diphosphate ->
trans,trans-farnesyl diphosphate +
diphosphate 2.5.1.1:
dimethylallyl diphosphate +
isopentenyl diphosphate =
geranyl diphosphate + diphosphate
2.5.1.10: geranyl diphosphate +
isopentenyl diphosphate ->
trans,trans-farnesyl diphosphate +
diphosphate 2.5.1.1:
dimethylallyl diphosphate +
isopentenyl diphosphate =
geranyl diphosphate + diphosphate
Inhibitors – – – risedronate (pIC50 8.4) [31],
zoledronic acid (pKi 7.1) [121],
alendronate (pIC50 6.3) [31]
Selective
inhibitors
– – – ibandronic acid (pKi 6.7) [121],
pamidronic acid (pIC50 6.7) [121]
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Nomenclature squalene synthase squalene monooxygenase lanosterol synthase
HGNC, UniProt FDFT1, P37268 SQLE, Q14534 LSS, P48449
EC number 2.5.1.21: 2trans,trans-farnesyl diphosphate ->
presqualene diphosphate + diphosphate
presqualene diphosphate + NAD(P)H + H+ -> squalene
+ diphosphate + NAD(P)+
1.14.13.132: H+ + NADPH + O2 +
squalene = H2O + NADP
+ +
(S)-2,3-epoxysqualene
5.4.99.7: (S)-2,3-epoxysqualene = lanosterol
Cofactors NADPH – –
Inhibitors zaragozic acid A (pKi 10.1) [32] – Rat, zaragozic acid A
(pIC50 9.2) [488]
– –
Further Reading
Miziorko HM. (2011) Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Arch. Biochem.
Biophys. 505: 131-43 [PMID:20932952]
Rozman D et al. (2010) Perspectives of the non-statin hypolipidemic agents. Pharmacol. Ther. 127:
19-40 [PMID:20420853]
Seiki S et al. (2009) Pharmacologic inhibition of squalene synthase and other downstream enzymes
of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholes-
terolemia. Cardiol Rev 17: 70-6 [PMID:19367148]
Zhang H et al. (2014) Cholesterol and lipoprotein metabolism: Early Career Committee contribution.
Arterioscler. Thromb. Vasc. Biol. 34: 1791-4 [PMID:25142876]
van der Burgh R et al. (2012) Mevalonate kinase deficiency, a metabolic autoinflammatory disease.
Clin. Immunol. [PMID:23110805]
Nucleoside synthesis and metabolism
Enzymes! Nucleoside synthesis and metabolism
Overview: The de novo synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces tetrahy-
drofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate
dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.
Nomenclature dihydrofolate reductase dihydroorotate dehydrogenase IMP (inosine 5’-monophosphate) IMP (inosine 5’-monophosphate)
(quinone) dehydrogenase 1 dehydrogenase 2
HGNC, UniProt DHFR, P00374 DHODH, Q02127 IMPDH1, P20839 IMPDH2, P12268
EC number 1.5.1.3 1.3.5.2 1.1.1.205 1.1.1.205
Searchable database: http://www.guidetopharmacology.org/index.jsp Nucleoside synthesis and metabolism 6097
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13354/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. British Journal of Pharmacology (2015) 172, 6024–6109
(continued)
Nomenclature dihydrofolate reductase dihydroorotate dehydrogenase IMP (inosine 5’-monophosphate) IMP (inosine 5’-monophosphate)
(quinone) dehydrogenase 1 dehydrogenase 2
Inhibitors pemetrexed (pKi 8.1)
[161, 436], pralatrexate
(pKi 7.3) [231]
teriflunomide (pKi 7.5) [204],
leflunomide (pKi 4.9) [372]
mycophenolic acid (pIC50 7.7)
[351], ribavirin (pIC50 5.6–6)
[526], mycophenolate mofetil,
thioguanine [124, 502]
mycophenolic acid (pIC50 7.7) [351],
ribavirin (pIC50 5.6–6) [526],
mycophenolate mofetil (See Inhibitor
Comment below), thioguanine [124,
502]
Selective inhibitors methotrexate (pKi 8.9)
[412]
– – –
Nomenclature xanthine dehydrogenase ribonucleotide reductase M1 ribonucleotide reductase M2 ribonucleotide reductase M2
B (TP53 inducible)
HGNC, UniProt XDH, P47989 RRM1, P23921 RRM2, P31350 RRM2B, Q7LG56
EC number 1.17.1.4 1.17.14.1 1.17.4.1 1.17.1.4
Inhibitors febuxostat (pKi 9.9)
[361] – Bovine,
febuxostat (pIC50 7.5)
[255] – Bovine,
allopurinol (pIC50 5.4)
[34], allopurinol (pKi 5.2)
[34]
clofarabine (pIC50 8.3) [375],
fludarabine (pIC50 6) [491],
hydroxyurea (pIC50 3.8) [433],
gemcitabine [205]
clofarabine (pIC50 8.3) [375],
fludarabine (pIC50 6) [491],
hydroxyurea (pIC50 3.8) [433],
gemcitabine [205]
–
Nomenclature thymidylate synthetase phosphoribosylglycinamide formyltransferase, purine nucleoside phosphorylase
phosphoribosylglycinamide synthetase,
phosphoribosylaminoimidazole synthetase
Common abreviation – GART –
HGNC, UniProt TYMS, P04818 GART, P22102 PNP, P00491
EC number 2.1.1.45 2.1.2.2 –
6.3.3.1
6.3.4.13
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Nomenclature thymidylate synthetase phosphoribosylglycinamide formyltransferase, purine nucleoside phosphorylase
phosphoribosylglycinamide synthetase,
phosphoribosylaminoimidazole synthetase
Inhibitors pemetrexed (pKi 7) [436], capecitabine [63,
373]
pemetrexed (pKi 5) [436] – Mouse –
Selective inhibitors raltitrexed (pIC50 6.5) [162] – –
Comments: Thymidylate synthetase allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. Purine nucleoside phosphorylase allows separation of a nucleoside
into the nucleobase and ribose phosphate for nucleotide salvage. Xanthine dehydrogenase generates urate in the purine degradation pathway. Post-translational modifications of xanthine dehydrogenase
convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species. Ribonucleotide
reductases allow the production of deoxyribonucleotides from ribonucleotides.
Further Reading
Battelli MG et al. (2014) Pathophysiology of circulating xanthine oxidoreductase: new emerging
roles for a multi-tasking enzyme. Biochim. Biophys. Acta 1842: 1502-17 [PMID:24882753]
Cantu-Medellin N et al. (2013) Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric ox-
ide: insights regarding where, when and how. Nitric Oxide 34: 19-26 [PMID:23454592]
Glander P et al. (2012) Inosine 5’-monophosphate dehydrogenase activity as a biomarker in the field
of transplantation. Clin. Chim. Acta 413: 1391-7 [PMID:21889500]
Munier-Lehmann H et al. (2013) On dihydroorotate dehydrogenases and their inhibitors and uses.
J. Med. Chem. 56: 3148-67 [PMID:23452331]
Sphingosine 1-phosphate turnover
Enzymes! Sphingosine 1-phosphate turnover
Overview: S1P (sphingosine 1-phosphate) is a pro-survival sig-
nal, in contrast to ceramide. It is formed by the sphingosine
kinase-catalysed phosphorylation of sphingosine. S1P can be
released from cells to act as an agonist at a family of five G
protein-coupled receptors (S1P1-5) but also has intracellular tar-
gets. S1P can be dephosphorylated back to sphingosine or hy-
drolysed to form hexadecanal and phosphoethanolamine. Sphin-
gosine choline phosphotransferase (EC 2.7.8.10) generates sphin-
gosylphosphocholine from sphingosine and CDP-choline. Sphin-
gosine β-galactosyltransferase (EC 2.4.1.23) generates psychosine
from sphingosine in the presence of UDP-α-D-galactose. The
molecular identities of these enzymes have not been confirmed.
Further Reading
Chan H et al. (2013) Post-translational regulation of sphingosine kinases. Biochim. Biophys. Acta
1831: 147-56 [PMID:22801036]
Khavandgar Z et al. (2015) Sphingolipid metabolism and its role in the skeletal tissues. Cell. Mol.
Life Sci. 72: 959-69 [PMID:25424644]
Maceyka M et al. (2014) Sphingolipid metabolites in inflammatory disease. Nature 510: 58-67
[PMID:24899305]
Plano D et al. (2014) Importance of sphingosine kinase (SphK) as a target in developing cancer ther-
apeutics and recent developments in the synthesis of novel SphK inhibitors. J. Med. Chem. 57:
5509-24 [PMID:24471412]
Pyne S et al. (2011) Translational aspects of sphingosine 1-phosphate biology. Trends Mol Med 17:
463-72 [PMID:21514226]
Rosen H et al. (2013) Sphingosine-1-phosphate and its receptors: structure, signaling, and influence.
Annu. Rev. Biochem. 82: 637-62 [PMID:23527695]
Schwalm S et al. (2014) Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to
treat chronic inflammatory kidney diseases. Basic Clin. Pharmacol. Toxicol. 114: 44-9
[PMID:23789924]
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Sphingosine kinase
Enzymes! Sphingosine 1-phosphate turnover! Sphingosine kinase
Nomenclature sphingosine kinase 1 sphingosine kinase 2
Common abreviation SPHK1, SPHK2
HGNC, UniProt SPHK1, Q9NYA1 SPHK2, Q9NRA0
EC number 2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + adenosine diphosphate
ATP + sphinganine = sphinganine 1-phosphate + adenosine diphosphate
Cofactors Mg2+ [432]
Inhibitors PF-543 (pIC50 8.7) [425], SK1-I [377], ABC294640 [148], ROMe [287]
(Sub)family-selective inhibitors sphingosine kinase inhibitor (pIC50 6.3) [147]
Further Reading
Neubauer HA et al. (2013) Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J. 280:
5317-36 [PMID:23638983]
Truman JP et al. (2014) Evolving concepts in cancer therapy through targeting sphingolipid
metabolism. Biochim. Biophys. Acta 1841: 1174-88 [PMID:24384461]
Sphingosine 1-phosphate phosphatase
Enzymes! Sphingosine 1-phosphate turnover! Sphingosine 1-phosphate phosphatase
Nomenclature sphingosine-1-phosphate phosphatase 1 sphingosine-1-phosphate phosphatase 2
Common abreviation SGPP1 SGPP2
HGNC, UniProt SGPP1, Q9BX95 SGPP2, Q8IWX5
EC number 3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic phosphate 3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic phosphate
Comments Depletion of S1P phosphohydrolase-1 (SPP1), which degrades intracellular
S1P, induces the unfolded protein response and endoplasmic reticulum
stress-induced autophagy [307].
–
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Sphingosine 1-phosphate lyase
Enzymes! Sphingosine 1-phosphate turnover! Sphingosine 1-phosphate lyase
Nomenclature sphingosine-1-phosphate lyase 1
HGNC, UniProt SGPL1, O95470
EC number 4.1.2.27: sphingosine 1-phosphate -> phosphoethanolamine + hexadecanal
Cofactors pyridoxal phosphate
Inhibitors compound 31 [PMID: 24809814] (pIC50 6.7) [519]
Comments THI (2-Acetyl-5-tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations [426].
Further Reading
Bigaud M et al. (2014) Second generation S1P pathway modulators: research strategies and clinical
developments. Biochim. Biophys. Acta 1841: 745-58 [PMID:24239768]
Van Veldhoven PP et al. (2000) Human sphingosine-1-phosphate lyase: cDNA cloning, functional
expression studies and mapping to chromosome 10q22(1). Biochim. Biophys. Acta 1487: 128-34
[PMID:11018465]
Thyroid hormone turnover
Enzymes! Thyroid hormone turnover
Overview:
The thyroid hormones triiodothyronine and thyroxine, usually
abbreviated as triiodothyronine and T4, respectively, are synthe-
sized in the thyroid gland by sequential metabolism of tyrosine
residues in the glycosylated homodimeric protein thyroglobulin
(TG, P01266) under the influence of the haem-containing protein
iodide peroxidase. Iodide peroxidase/TPO is a haem-containing
enzyme, from the same structural family as eosinophil peroxidase
(EPX, P11678), lactoperoxidase (LPO, P22079) and myeloperox-
idase (MPO, P05164). Circulating thyroid hormone is bound to
thyroxine-binding globulin (SERPINA7, P05543).
Tissue deiodinases
These are 1 TM selenoproteins that remove an iodine from
T4 (3,3’,5,5’-tetraiodothyronine) to generate triiodothyronine
(3,3’,5-triiodothyronine, a more potent agonist at thyroid hor-
mone receptors) or rT3 (rT3, 3,3’,5’-triiodothyronine, a relatively
inactive analogue). DIO1 is also able to deiodinate RT3 to form
3,3’-diidothyronine (T2). Iodotyrosine deiodinase is a 1TM ho-
modimeric enzyme.
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Nomenclature thyroid peroxidase deiodinase, iodothyronine, deiodinase, iodothyronine, deiodinase, iodothyronine,
iodotyrosine deiodinase
type I type II type III
Common
abreviation
TPO DIO1 DIO2 DIO3 IYD
HGNC,
UniProt
TPO, P07202 DIO1, P49895 DIO2, Q92813 DIO3, P55073 IYD, Q6PHW0
EC number 1.11.1.8:
[Thyroglobulin]-L-tyrosine +
H2O2 + H
+ + I- ->
[Thyroglobulin]-3,5,3’-
triiodo-L-thyronine +
[thyroglobulin]-aminoacrylate
+ H2O
1.97.1.10: T4 ->
triiodothyronine
rT3 -> T2
1.97.1.10: T4 ->
triiodothyronine
rT3 -> T2
1.97.1.11: T4 ->
triiodothyronine
rT3 -> T2
1.22.1.1:
3-iodotyrosine ->
L-tyrosine + I-
3,5-diiodo-L-tyrosine
-> 3-iodotyrosine + I-
Cofactors Ca2+ – – –
flavin adenine dinucleotide,
NADPH
Inhibitors methimazole [349],
propylthiouracil [349]
– – – –
Comments Carbimazole is a pro-drug for
methimazole
– – – –
Further Reading
Arrojo E Drigo R et al. (2013) Role of the type 2 iodothyronine deiodinase (D2) in the control of
thyroid hormone signaling. Biochim. Biophys. Acta 1830: 3956-64 [PMID:22967761]
Darras VM et al. (2015) Intracellular thyroid hormone metabolism as a local regulator of nuclear
thyroid hormone receptor-mediated impact on vertebrate development. Biochim. Biophys. Acta
1849: 130-41 [PMID:24844179]
Darras VM et al. (2012) Iodothyronine deiodinase structure and function: from ascidians to humans.
J. Endocrinol. 215: 189-206 [PMID:22825922]
Gereben B et al. (2008) Cellular and molecular basis of deiodinase-regulated thyroid hormone sig-
naling. Endocr. Rev. 29: 898-938 [PMID:18815314]
Waung JA et al. (2012) Thyroid hormone metabolism in skeletal development and adult bone main-
tenance. Trends Endocrinol. Metab. 23: 155-62 [PMID:22169753]
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1.14.11.29 2-oxoglutarate oxygenases
Enzymes! 1.14.11.29 2-oxoglutarate oxygenases
Overview: The hypoxia inducible factor (HIF) is a transcriptional
complex that is involved in oxygen homeostasis [429]. At nor-
mal oxygen levels, the alpha subunit of HIF (HIF-1α) is targeted
for degradation by prolyl hydroxylation by the PHD proteins 1-3
(HIF-PHs) whch are 2-oxoglutarate (2OG) oxygenases responsible
for the post-translational modification of a specific proline in each
of the oxygen-dependent degradation (ODD) domains of HIF-1α.
Hydroxylated HIFs are then targeted for proteasomal degradation
via the von Hippel-Lindau ubiquitination complex [232]. Under
hypoxic conditions, the hydroxylation reaction is blunted which
results in decreased HIF degradation. The surviving HIFs are then
available to translocate to the nucleus where they heterodimerize
with HIF-1β, effecting increased expression of hypoxia-inducible
genes.
HIF-PH enzymes are being investigated as pharmacological targets
as their inhibition mimics the hypoxic state and switches on tran-
scription of genes associated with processes such as erythropoiesis
and vasculogenesis [142]. Small molecule HIF-PH inhibitors are
in clinical trial as novel therapies for the amelioration of anemia
associated with chronic kidney disease [46].
Nomenclature egl-9 family hypoxia-inducible factor 2 egl-9 family hypoxia-inducible factor 1 egl-9 family hypoxia-inducible factor 3
Common abreviation PHD1 PHD2 PHD3
HGNC, UniProt EGLN2, Q96KS0 EGLN1, Q9GZT9 EGLN3, Q9H6Z9
EC number – 1.14.11.29 1.14.11.29
Inhibitors – IOX2 (pIC50 7.7) [84] –
2.4.2.30 poly(ADP-ribose)polymerases
Enzymes! 2.4.2.30 poly(ADP-ribose)polymerases
Overview: The Poly ADP-ribose polymerase family is a series of enzymes, where the best characterised members are nuclear proteins which are thought to function by binding to single strand breaks in
DNA, allowing the recruitment of repair enzymes by the synthesis of NAD-derived ADP-ribose polymers, which are subsequently degraded by a glycohydrolase (PARG, Q86W56).
Nomenclature poly (ADP-ribose) polymerase 1 poly (ADP-ribose) polymerase 2 poly (ADP-ribose) polymerase 3
Common abreviation PARP1 PARP2 PARP3
HGNC, UniProt PARP1, P09874 PARP2, Q9UGN5 PARP3, Q9Y6F1
EC number 2.4.2.30 2.4.2.30 –
Selective inhibitors AG14361 (pKi 8.2) [445] – –
Searchable database: http://www.guidetopharmacology.org/index.jsp 2.4.2.30 poly(ADP-ribose)polymerases 6103
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De Vos M et al. (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair:
current state of the art. Biochem. Pharmacol. 84: 137-46 [PMID:22469522]
Lord CJ et al. (2012) The DNA damage response and cancer therapy. Nature 481: 287-94
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Sonnenblick A et al. (2015) An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev
Clin Oncol 12: 27-41 [PMID:25286972]
2.5.1.58 Protein farnesyltransferase
Enzymes! 2.5.1.58 Protein farnesyltransferase
Overview: Farnesyltransferase is a member of the prenyltrans-
ferases family which also includes geranylgeranyltransferase types
I (EC 2.5.1.59) and II (EC 2.5.1.60) [66]. Protein farnesyltransferase
catalyses the post-translational formation of a thioether linkage
between the C-1 of an isoprenyl group and a cysteine residue
fourth from the C-terminus of a protein (ie to the CaaX motif,
where ’a’ is an aliphatic amino acid and ’X’ is usually serine, me-
thionine, alanine or glutamine; leucine for EC 2.5.1.59) [156]. Far-
nesyltransferase is a dimer, composed of an alpha and beta subunit
and requires Mg2+ and Zn2+ ions as cofactors. The active site is
located between the subunits. Prenylation creates a hydrophobic
domain on protein tails which acts as a membrane anchor.
Substrates of the prenyltransferases include Ras, Rho, Rab, other
Ras-related small GTP-binding proteins, G-protein γ-subunits, nu-
clear lamins, centromeric proteins and many proteins involved in
visual signal transduction.
In relation to the causative association between oncogenic Ras
proteins and cancer, farnesyltransferase has become an important
mechanistic drug discovery target.
3.5.3.15 Peptidyl arginine deiminases (PADI)
Enzymes! 3.5.3.15 Peptidyl arginine deiminases (PADI)
Overview: In humans, the peptidyl arginine deiminases (PADIs; HGNC family link) are a family of five enzymes, PADI1-4 and PADI6. PADIs catalyze the deimination of protein L-arginine residues to
L-citrulline and ammonia. The human isozymes exhibit tissue-specific expression patterns [244].
RAS subfamily
Enzymes! 3.6.5.2 Small monomeric GTPases! RAS subfamily
Overview: The RAS proteins (HRAS, NRAS and KRAS) are small
membrane-localised G protein-like molecules of 21 kd. They act as
an on/off switch linking receptor and non-receptor tyrosine kinase
activation to downstream cytoplasmic or nuclear events. Binding
of GTP activates the switch, and hydrolysis of the GTP to GDP
inactivates the switch.
The RAS proto-oncogenes are the most frequently mutated class
of proteins in human cancers. Common mutations compromise
the GTP-hydrolysing ability of the proteins causing constitutive
activation [457], which leads to increased cell proliferation and
decreased apoptosis [550]. Because of their importance in onco-
genic transformation these proteins have become the targets of
intense drug discovery effort [23].
Searchable database: http://www.guidetopharmacology.org/index.jsp RAS subfamily 6104
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4.2.1.1 Carbonate dehydratases
Enzymes! 4.2.1.1 Carbonate dehydratases
Overview: Carbonic anhydrases facilitate the interconversion of water and carbon dioxide with bicarbonate ions and protons (EC 4.2.1.1), with over a dozen gene products identified in man. The
enzymes function in acid-base balance and the movement of carbon dioxide and water. They are targetted for therapeutic gain by particular antiglaucoma agents and diuretics.
Nomenclature carbonic anhydrase I carbonic anhydrase VII carbonic anhydrase XII
HGNC, UniProt CA1, P00915 CA7, P43166 CA12, O43570
EC number 4.2.1.1 4.2.1.1 4.2.1.1
Inhibitors chlorthalidone (pKi 6.5) methazolamide (pKi 8.7) [430], acetazolamide
(pKi 8.6) [18], brinzolamide (pKi 8.6) [430],
chlorthalidone (pKi 8.6) [482]
chlorthalidone (pKi 8.4) [482], diclofenamide (pKi
7.3) [504]
Further Reading
Alterio V et al. (2012) Multiple binding modes of inhibitors to carbonic anhydrases: how to design
specific drugs targeting 15 different isoforms? Chem. Rev. 112: 4421-68 [PMID:22607219]
Cummins EP et al. (2014) Carbon dioxide-sensing in organisms and its implications for human
disease. Cell. Mol. Life Sci. 71: 831-45 [PMID:24045706]
Imtaiyaz HassanM et al. (2013) Structure, function and applications of carbonic anhydrase isozymes.
Bioorg. Med. Chem. 21: 1570-82 [PMID:22607884]
Sjöblom M. (2011) Duodenal epithelial sensing of luminal acid: role of carbonic anhydrases. Acta
Physiol (Oxf) 201: 85-95 [PMID:20632999]
5.99.1.2 DNA Topoisomerases
Enzymes! 5.99.1.2 DNA Topoisomerases
Overview: DNA topoisomerases regulate the supercoiling of nuclear DNA to influence the capacity for replication or transcription. The enzymatic function of this series of enzymes involves cutting the
DNA to allow unwinding, followed by re-attachment to reseal the backbone. Members of the family are targetted in anti-cancer chemotherapy.
Nomenclature topoisomerase (DNA) I topoisomerase (DNA) II alpha 170kDa
HGNC, UniProt TOP1, P11387 TOP2A, P11388
EC number 5.99.1.2 5.99.1.2
Inhibitors irinotecan [117, 477] – Bovine etoposide (pIC50 7.3), teniposide [119] – Mouse
Searchable database: http://www.guidetopharmacology.org/index.jsp 5.99.1.2 DNA Topoisomerases 6105
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